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hsa-laHa-UGAGGUAGUAGGUUGUAUAGUU - SEQ ID NO , 
tisa·let-7t>-UGAGGUAGUAGGUUGUGUGGUU - SEQ 10 NO 2 
Ma-lat-7c-UGAGGUAGUAGGUUGUAUGGUU - SEQ ID NO 3 
Ma-tet-711-AGAGGUAGUAGGUUGCAUAGUU. SEQ ID NO 4 
hsa-let-7&-UGAGGUAGGAGGUUGUAUAGUU ·SEO 10 NO S 
hsa-~t-7!-UGAGGUAGUAGAUUGUAUAGUU ·SEQ ID NO 6 
hsa-ieH~UGAGGUAGUAGUUUGUACAGUU ·SEQ ID NO 7 
hS8·1et-7~UGAGGUAGUAGUUUGUGCUGUU ·SEQ ID NO· 8 
hsa-mlR-7-UGGAAGACUAGUGAUUUUGUUGU. SEQ ID NO: 9 
hsa-mlR-158-UAGCAGCACAUAAUGGUUUGUG - SEQ ID NO 10 
hsa·mlR-15b·UAGCAGCACAUCAUGGUUUACA ·SEQ 10 NO. 11 
nsa-m•R-16-UAGCAGCACGUAAAUAUUGGCG. SEQ 10 NO 12 
Ma-mlR-17-CAAAGUGCUUACAGUGCAGGUAG - SEQ ID NO 13 
hsa·'™R-11!a·UAAGGUGCAUCUAGUGCAGAUAG - SEQ ID NO 14 
h""·m1R-181l.UAAGGUGCAUCUAGUGCAGUUAG ·SEQ ID NO· 15 
hsa-m1R-11!a"-ACUGCCCUAAGUGCUCCUUCUGG ·SEQ ID NO 16 
h ... m1R-19a.UGUGCAAAUCUAUGCAAAACUGA- SEQ ID NO 17 
hsa-mlR-20..-UAAAGUGCUUAUAGUGCAGGUAG ·SEQ ID NO. 18 
h .. ·ITllR-25-CAUUGCACUUGUCUCGGUCUGA - sea ID NO 19 
h:;a-m!A-25b--UUCAAGUAAUUCAGGAUAGGU ·SEQ ID NO· 20 
hsa-miR-JOb-UGUAMCAUCCUACACUCAGCU - SEO ID NO 21 
hsa-mlR-30a-UGUAAACAUCCUCGACUGGAAG - SEO ID NO· 22 
hsa-mll'l-3Cle- UGUAAACAUCCUUGACUGGAAG- pr~IB!Ted ·SEO ID NO· 23 
hsa-mll'l-93-CAMGUGCUGUUCGUGCAGGUAG ·SEQ ID NO· 24 
hsa-m•R-95-UUUOOCACUAGCACAUUUUUGCU ·SEQ ID NO. 25 
hsa-moR-103-AGCAGCAUUGUACAGGGCUAUGA- sea ID NO 26 
//hsa-miR-107-AGCAGCAUUGUACAGGGCUAUCA. sea ID NO 29 
h$1i-mlR-106o-AAAAGUGCUUACAGUGCAGGUAG - sea ID NO 27 
// hsa-m•Fl-1 7-CAAAGUGCUUACAGUGCAGGUAG • SEQ 10 NO 1 3 
hsa-m1R-106~UAAAGUGCUGACAGUGCAGAU - SEQ ID NO 28 
hsa-mlR-107-AGCAGCAUUGUACAGGGCUAUCA- SEQ 10 NO 29 
h:!<l·mlR· 1 26-UCGUACCGUGAGUAAUAAUGCG • SEO ID NO 30 
hsa-mlR-12e·-CAUUAUUACUUUUGGUACOCG-SEOIDNO 31 
has-miR-128-UCACAGUGAACCGGUCUCUUU ·SEQ ID NO. 32 
hsa-mlR-130a-CAGUGCAAUGUUAAAAOGGCAU - SEQ 10 NO: 33 
hs'1-m1R-14aa-UCAGUGCACUACAGAACUUUGU ·SEO ID NO 34 
hs•-mlR-14&-UCAGUGCAUCACAGAACUUUGU ·SEQ ID NO: 35 
hsi0-m1R·14Sa'·AAAGUUCUGAGACACUCCGACU ·SEQ ID NO 36 
hsa·miR-148b'-AAGUUCUGUUAUACACUCAGGC ·SEQ ID NO 37 
miR150 hsa-mlR-150-UCUCCCAACCCUUGUACCAGUG. sea 10 NO 36 
mlR151 hsa-m1R-151-5p·UCGAGGAGCUCACAGUCUAGU - SEQ ID NO 39 
hsa-mJR-151-Jp-CUAGACUGAAGCUCCUUGAGG- preferred - SEQ 10 NO: 40 
m<R181a hsa-m<R-1S1a·AACAUUCAACGCUGUCGGUGAGU ·SEQ ID NO 41 
m<R181c hsa-mlR-161c-AACAUUCAACCUGUCGGUGAGU -SEQ ID NO 42 
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hsa-let-7a-UGAGGUAGUAGGUUGUAUAGUU - SEQ ID NO: 1 
hsa-let-7b-UGAGGUAGUAGGUUGUGUGGUU - SEQ ID NO 2 
hsa-let-7c-UGAGGUAGUAGGUUGUAUGGUU - SEQ ID NO: 3 
hsa-let-7d-AGAGGUAGUAGGUUGCAUAGUU - SEQ ID NO: 4 
hsa-let-7e-UGAGGUAGGAGGUUGUAUAGUU - SEQ ID NO: 5 
hsa-let-7f-UGAGGUAGUAGAUUGUAUAGUU - SEQ ID NO: 6 
hsa-let-7g-UGAGGUAGUAGUUUGUACAGUU - SEQ ID NO: 7 
hsa-let-7i-UGAGGUAGUAGUUUGUGCUGUU - SEQ ID NO: 8 
hsa-miR-7-UGGAAGACUAGUGAUUUUGUUGU - SEQ ID NO: 9 
hsa-miR-15a-UAGCAGCACAUAAUGGUUUGUG - SEQ ID NO: 10 
hsa-miR-15b-UAGCAGCACAUCAUGGUUUACA- SEQ ID NO: 11 
hsa-miR-16-UAGCAGCACGUAAAUAUUGGCG - SEQ ID NO: 12 
hsa-miR-17-CAAAGUGCUUACAGUGCAGGUAG - SEQ ID NO: 13 
hsa-miR-18a-UAAGGUGCAUCUAGUGCAGAUAG - SEQ ID NO: 14 
hsa-miR-18b-UAAGGUGCAUCUAGUGCAGUUAG ·SEQ ID NO: 15 
hsa-miR-18a*-ACUGCCCUMGUGCUCCUUCUGG - SEQ ID NO: 16 
hsa-miR-19a-UGUGCMAUCUAUGCAAAACUGA- SEQ ID NO: 17 
hsa-m1R-20a-UAAAGUGCUUAUAGUGCAGGUAG ·SEQ ID NO: 18 
hsa-miR-25-CAUUGCACUUGUCUCGGUCUGA - SEQ ID NO: 19 
hsa-miR-26b-UUCMGUAAUUCAGGAUAGGU - SEQ ID NO: 20 
hsa-miR-30b-UGUAAACAUCCUACACUCAGCU - SEQ ID NO: 21 
hsa-miR-30a-UGUAAACAUCCUCGACUGGMG - SEQ ID NO: 22 
hsa-miR-30e- UGUAMCAUCCUUGACUGGAAG - preferred - SEQ ID NO: 23 
hsa-miR-93-CAAAGUGCUGUUCGUGCAGGUAG - SEQ ID NO: 24 
hsa-miR-96-UUUGGCACUAGCACAUUUUUGCU - SEQ ID NO: 25 
hsa-miR-103-AGCAGCAUUGUACAGGGCUAUGA- SEQ ID NO: 26 
II hsa-miR-107-AGCAGCAUUGUACAGGGCUAUCA- SEQ ID NO: 29 
hsa-miR-106a-AAAAGUGCUUACAGUGCAGGUAG - SEQ ID NO: 27 
II hsa-miR-17 -CAAAGUGCUUACAGUGCAGGUAG • SEQ ID NO: 13 
hsa-miR-106b-UMAGUGCUGACAGUGCAGAU ·SEQ ID NO: 28 
hsa-miR-107-AGCAGCAUUGUACAGGGCUAUCA- SEQ ID NO: 29 
hsa-miR-126-UCGUACCGUGAGUAAUAAUGCG - SEQ ID NO: 30 
hsa-miR-12a·-cAUUAUUACUUUUGGUACGCG - SEQ ID NO: 31 
has-miR-128-UCACAGUGMCCGGUCUCUUU - SEQ ID NO: 32 
hsa-miR-130a-CAGUGCAAUGUUAAAAGGGCAU - SEQ ID NO: 33 
hsa-miR-148a-UCAGUGCACUACAGMCUUUGU - SEQ ID NO 34 
hsa-miR-148b-UCAGUGCAUCACAGAACUUUGU - SEQ ID NO: 35 
hsa-miR-148a*-MAGUUCUGAGACACUCCGACU- SEQ ID NO: 36 
hsa-miR-148b*-AAGUUCUGUUAUACACUCAGGC - SEQ ID NO: 37 
hsa-miR-150-UCUCCCAACCCUUGUACCAGUG- SEQ ID NO: 38 
hsa-miR-151-Sp-UCGAGGAGCUCACAGUCUAGU - SEQ ID NO: 39 
hsa-miR-151-3p-CUAGACUGAAGCUCCUUGAGG - preferred - SEQ ID NO: 40 
hsa-miR-181a-AACAUUCMCGCUGUCGGUGAGU - SEQ ID NO: 41 
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hsa-miR-182-UUUGGCAAUGGUAGAACUCACACU - SEQ ID NO: 43 
hsa-miR-182°-UGGUUCUAGACUUGCCAACUA- SEQ ID NO: 44 
hsa-miR-183-UAUGGCACUGGUAGAAUUCACU - SEQ ID NO: 45 
hsa-miR-185-UGGAGAGAAAGGCAGUUCCUGA - SEQ ID NO: 46 
hsa-miR-190-UGAUAUGUUUGAUAUAUUAGGU - SEQ ID NO: 47 
hsa-miR-191-CAACGGAAUCCCAAAAGCAGCUG - SEQ ID NO: 48 
hsa-miR-194-UGUAACAGCAACUCCAUGUGGA - SEQ ID NO 49 
hsa-miR-195-UAGCAGCACAGAAAUAUUGGC - SEQ ID NO 50 
hsa-miR-210-CUGUGCGUGUGACAGCGGCUGA - SEQ ID NO 51 
hsa-miR-215-AUGACCUAUGAAUUGACAGAC- SEQ ID NO: 52 
hsa-miR-301a-CAGUGCAAUAGUAUUGUCAAAGC- preferred - SEQ ID NO 53 
hsa-miR-301b-CAGUGCAAUGAUAUUGUCAAAGC - SEQ ID NO 54 
miR324-3p hsa-miR-324-3p-ACUGCCCCAGGUGCUGCUGG - SEQ ID NO: 55 
miR331 hsa-miR-331-3p-GCCCCUGGGCCUAUCCUAGAA- preferred - SEQ JD NO: 56 
hsa-miR-331-5p-CUAGGUAUGGUCCCAGGGAUCC - SEQ ID NO 57 
m1R324-3p hsa-miR-324-Jp-ACUGCCCCAGGUGCUGCUGG - SEQ ID NO: 55 
























hsa-miR-339-3p-UGAGCGCCUCGACGACAGAGCCG - SEQ ID NO: 59 
hsa-miR-340-UUAUAAAGCAAUGAGACUGAUU - SEQ ID NO: 60 
hsa-miR-363·-CGGGUGGAUCACGAUGCAAUUU - SEQ ID NO: 61 
hsa-miR-374-UUAUAAUACAACCUGAUAAGUG - SEQ ID NO: 62 
hsa-miR-425-AAUGACACGAUCACUCCCGUUGA - SEQ ID NO: 63 
hsa-miR-451-AAACCGUUACCAUUACUGAGUU - SEQ ID NO: 119 
hsa-miR-484-UCAGGCUCAGUCCCCUCCCGAU - SEQ ID NO: 120 
hsa-miR-486-Sp-UCCUGUACUGAGCUGCCCCGAG - preferred - SEQ ID NO: 64 
hsa-miR-486-3p-CGGGGCAGCUCAGUACAGGAU - SEQ ID NO: 65 
hsa-miR-500-UAAUCCUUGCUACCUGGGUGAGA - SEQ ID NO: 66 
hsa-miR-545-UCAGCAAACAUUUAUUGUGUGC - SEQ ID NO: 67 
hsa-miR-548d-5p-AAAAGUAAUUGUGGUUUUUGCC - SEQ ID NO: 68 
hsa-miR-548d-3p-CAAAAACCACAGUUUCUUUUGC - preferred - SEQ ID NO: 69 
hsa-m1R-556-3p-AUAUUACCAUUAGCUCAUCUUU - SEQ ID NO 70 
hsa-miR-556-Sp-GAUGAGCUCAUUGUAAUAUGAG - preferred - SEQ ID NO 71 
hsa-m1R-576-3p-AAGAUGUGGAAAAAUUGGAAUC - SEQ ID NO: 72 
hsa-miR-576-5p-AUUCUAAUUUCUCCACGUCUUU - preferred - SEQ ID NO: 73 
hsa-miR-579-UUCAUUUGGUAUAAACCGCGAUU - SEQ ID NO: 74 
hsa-miR-580-UUGAGAAUGAUGAAUCAUUAGG - SEQ ID NO 75 
hsa-rniR-581-UCUUGUGUUCUCUAGAUCAGU - SEQ ID NO: 76 
hsa-miR-590-5p-GAGCUUAUUCAUAAAAGUGCAG - preferred - SEQ ID NO: 77 
hsa-miR-590-3p-UAAUUUUAUGUAUAAGCUAGU - SEQ ID NO: 78 
hsa-miR-624-CACAAGGUAUUGGUAUUACCU - SEQ ID NO: 79 
hsa-miR-627-GUGAGUCUCUAAGAAAAGAGGA ·SEQ ID NO: 80 
hsa-miR-651-UUUAGGAUAAGCUUGACUUUUG - SEQ ID NO: 81 
hsa-miR-652-AAUGGCGCCACUAGGGUUGUG - SEQ ID NO: 82 
hsa-miR-660-UACCCAUUGCAUAUCGGAGUUG - SEQ ID NO: 83 
hsa-miR-154·-AAUCAUACACGGUUGACCUAUU - SEQ ID NO: 84 
hsa-miR-607-GUUCAAAUCCAGAUCUAUAAC - SEQ ID NO: 85 
FIG. 1 (continued) 
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hsa-miR-23b-AUCACAUUGCCAGGGAUUACC • SEQ ID NO: 87 
hsa-miR-27b-UUCACAGUGGCUAAGUUCUGC - SEQ ID NO: 88 
hsa-miR-31-AGGCAAGAUGCUGGCAUAGCU - SEQ ID NO: 89 
hsa-miR-33 -GUGCAUUGUAGUUGCAUUGCA - SEQ ID NO: 90 
hsa-miR-33b-GUGCAUUGCUGUUGCAUUGC ·SEQ ID NO. 91 
hsa-miR-95-UUCAACGGGUAUUUAUUGAGCA. SEQ ID NO 92 
hsa-miR-106b-UAAAGUGCUGACAGUGCAGAU ·SEQ ID NO: 28 
hsa-miR·125a-3p-ACAGGUGAGGUUCUUGGGAGCC- SEQ ID NO: 93 
hsa-miR-125a-5p-UCCCUGAGACCCUUUAACCUGUGA- preferred - SEQ ID 
N0:94 
hsa-miR-125b-UCCCUGAGACCCUAACUUGUGA ·SEQ ID NO: 95 
hsa-miR-136-ACUCCAUUUGUUUUGAUGAUGGA - SEQ ID NO: 96 
hsa-miR-141-UAACACUGUCUGGUAAAGAUGG - SEQ ID NO: 97 
hsa-miR-143-UGAGAUGAAGCACUGUAGCUC - SEQ ID NO: 98 
hsa-miR-154-UAGGUUAUCCGUGUUGCCUUCG - SEQ ID NO: 99 
hsa-miR-181b-AACAUUCAUUGCUGUCGGUGGGU - SEQ ID NO: 100 
hsa - miR24' - UGCCUACUGAGCUGAUAUCAGU- SEQ ID NO: 101 
hsa-miR-193b-AACUGGCCCUCAAAGUCCCGCU - SEQ ID NO: 102 
hsa-miR-199a-3p-ACAGUAGUCUGCACAUUGGUUA- SEQ ID NO: 103 
hsa-miR-199a-5p-CCCAGUGUUCAGACUACCUGUUC- preferred - SEQ ID NO 
104 
hsa-miR-199b-5p-CCCAGUGUUUAGACUAUCUGUUC- preferred - SEQ ID NO: 
105 
hsa-miR-199b-3p-ACAGUAGUCUGCACAUUGGUUA- SEQ ID NO. 103 
hsa-miR-200b-UAAUACUGCCUGGUAAUGAUGA - SEQ ID NO: 106 
hsa-miR-200c-UAAUACUGCCGGGUAAUGAUGGA ·SEQ ID NO: 107 
hsa-miR-203-GUGAAAUGUUUAGGACCACUAG - SEQ ID NO: 108 
hsa-miR-218-UUGUGCUUGAUCUAACCAUGU - SEQ ID NO: 109 
hsa-miR-223-UGUCAGUUUGUCAAAUACCCCA - SEQ ID NO 110 
hsa-miR-337-3p-CUCCUAUAUGAUGCCUUUCUUC-preferred- SEQ ID NO: 111 
hsa-miR-337-5p-GAACGGCUUCAUACAGGAGUU - SEQ ID NO: 112 
hsa-miR-377-AUCACACAAAGGCAACUUUUGU - SEQ ID NO: 113 
hsa-miR-382-GAAGUUGUUCGUGGUGGAUUCG - SEQ ID NO 114 
hsa-miR-412-ACUUCACCUGGUCCACUAGCCGU - SEQ ID NO: 115 
hsa-m1R-423-3p-AGCUCGGUCUGAGGCCCCUCAGU - preferred - SEQ ID NO· 
116 
hsa-miR-423-5p-UGAGGGGCAGAGAGCGAGACUUU ·SEQ ID NO: 117 
hsa-miR-425-3p - UAGUGCAAUAUUGCUUAUAGGGU ·SEQ ID NO. 118 
hsa-miR-451-AAACCGUUACCAUUACUGAGUU ·SEQ ID NO: 119 
hsa-miR-484-UCAGGCUCAGUCCCCUCCCGAU ·SEQ ID NO: 120 
hsa-miR-384-AUUCCUAGAAAUUGUUCAUA ·SEQ ID NO: 121 
hsa-miR-382-GAAGUUGUUCGUGGUGGAUUCG - SEQ ID NO· 114 
hsa-miR-429-UAAUACUGUCUGGUAAAACCGU · SEQ ID NO: 122 
hsa-miR-431-UGUCUUGCAGGCCGUCAUGCA- SEQ ID NO: 123 
hsa-miR-452-AACUGUUUGCAGAGGAAACUGA - SEQ ID NO: 124 
hsa-mlR-452·-cucAUCUGCAAAGAAGUAAGUG - SEQ ID NO: 125 
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hsa-miR-497-CAGCAGCACACUGUGGUUUGU - SEQ ID NO: 127 
hsa-miR-517'-CCUCUAGAUGGAAGCACUGUCU - SEQ ID NO: 128 
hsa-miR-611-GCGAGGACCCCUCGGGGUCUGAC - SEQ ID NO: 176 
hsa-miR-633-CUAAUAGUAUCUACCACAAUAAA- SEQ ID NO: 129 
hsa-miR-637 -ACUGGGGGCUUUCGGGCUCUGCGU - SEQ ID NO: 130 
hsa-miR-641-AAAGACAUAGGAUAGAGUCACCUC ·SEQ ID NO: 131 
hsa-miR-648-AAGUGUGCAGGGCACUGGU - SEQ ID NO: 132 
hsa-miR-211-UUCCCUUUGUCAUCCUUCGCCU ·SEQ ID NO: 133 
hsa-miR-216a-UAAUCUCAGCUGGCAACUGUGA - preferred ·SEQ ID NO: 192 
hsa-miR-216b-AAAUCUCUGCAGGCAAAUGUGA - SEQ ID NO: 191 
hsa-miR-369-Sp-AGAUCGACCGUGUUAUAUUCGC - SEQ ID NO: 134 
hsa-miR-376a-AUCAUAGAGGAAAAUCCACGU - SEQ ID NO: 135 
hsa-miR-376b-AUCAUAGAGGAAAAUCCAUGUU - SEQ ID NO: 136 
hsa-miR-379-UGGUAGACUAUGGAACGUAGG - SEQ ID NO: 137 
hsa-miR-489-GUGACAUCACAUAUACGGCAGC - SEQ ID NO: 138 
hsa-miR-507-UUUUGCACCUUUUGGAGUGAA- SEQ ID NO: 139 
FIG. 2(continued) 
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Human'miRNAs , • . · ·. . . v · . . •. 
hsa-miR-10b~UACCCUGUAGAACCGAAUUUGUG -·SEQ IDNO: 140 .. 
hsa-miR-99a-AACCCGUAGAUCCGAUCUUGUG - SEO ID NO: 141 
hsa-miR-100-AACCCGUAGAUCCGAACUUGUG - SEQ ID NO: 142 
hsa-m1R-135a-UAUGGCUUUUUAUUCCUAUGUGA- SEQ ID NO 143 
hsa-m1R-135b-UAUGGCUUUUCAUUCCUAUGUGA- SEQ ID NO: 144 
hsa-miR-149-UCUGGCUCCGUGUCUUCACUCCC - SEQ ID NO: 145 
hsa-mlR-204-UUCCCUUUGUCAUCCUAUGCCU - SEQ ID NO: 146 
hsa-miR-449a-UGGCAGUGUAUUGUUAGCUGGU- preferred - SEO ID NO: 147 
hsa-miR-449b-AGGCAGUGUAUUGUUAGCUGGC - SEQ ID NO 148 
hsa-miR-508-3p-UGAUUGUAGCCUUUUGGAGUAGA - preferred - SEQ ID NO: 
149 
hsa-miR-508-5p-UACUCCAGAGGGCGUCACUCAUG • SEQ ID NO: 150 
hsa-miR-513-UUCACAGGGAGGl)GUCAU - SEQ ID NO: 151 
hsa-miR-517a-AUCGUGCAUCCCUUUAGAGUGU - SEQ ID NO 152 
hsa-miR-518!'-CUCUAGAGGGAAGCACUUUCUC - SEQ ID NO: 153 
hsa-m1R-519d·CAAAGUGCCUCCCUUUAGAGUG - SEO ID NO: 154 
hsa-miR-519e-AAGUGCCUCCUUUUAGAGUGUU - SEQ ID NO: 155 
hsa-miR-520a-3p-AAAGUGCUUCCCUUUGGACUGU - SEQ ID NO: 156 
hsa-miR-520a 0 -AAAGUGCUUCCCUUUGGACUGU - SEQ ID NO: 156 
hsa-miR-520e-AAAGUGCUUCCUUUUUGAGGG- SEQ 10 NO: 157 
hsa-miR-520g-ACAAAGUGCUUCCCUUUAGAGUGU - SEQ ID NO: 158 
II hsa-miR-520h-ACAAAGUGCUUCCCUUUAGAGU - SEQ ID NO: 159 
hsa-miR-555-AGGGUAAGCUGAACCUCUGAU - SEQ ID NO: 224 
hsa-miR-509-3-5p-UACUGCAGACGUGGCAAUCAUG - SEQ ID NO 160 
hsa-miR-509-3p-UGAUUGGUACGUCUGUGGGUAG - preferred - SEQ ID NO: 
161 
hsa-miR-514-AUUGACACUUCUGUGAGUAGA ·SEQ ID NO. 162 
hsa-miR-515-5p-UUCUCCAAAAGAAAGCACUUUCUG - SEQ ID NO: 204 
has-miR-516a-3p-UGCUUCCUUUCAGAGGGU - SEQ ID NO: 163 
hsa-miR-517'-CCUCUAGAUGGAAGCACUGUCU - SEQ ID NO: 128 
hsa-miR-518a-5p-CUGCAAAGGGAAGCCCUUUC - SEQ ID NO: 164 
hsa-miR-518a-3p-GAAAGCGCUUCCCUUUGCUGGA- preferred - SEQ ID 
N0:165 
hsa-miR-518c-CAAAGCGCUUCUCUUUAGAGUGU - SEQ ID NO: 166 
hsa-miR-518e·AAAGCGCUUCCCUUCAGAGUG - SEQ ID NO: 167 
hsa-m1R-519e 0 -UUCUCCAAAAGGGAGCACUUUC - SEQ ID NO 168 
hsa-m1R-520d-5p-CUACAAAGGGAAGCCCUUUC - SEQ ID NO: 169 
hsa-miR-520d-3p-AAAGUGCUUCUCUUUGGUGGGU - SEQ ID NO: 170 
hsa-miR-521-AACGCACUUCCCUUUAGAGUGU - SEQ ID NO: 182 
hsa-miR-524-3p-GAAGGCGCUUCCCUUUGGAGU ·SEQ ID NO: 171 
hsa-miR-524-Sp-CUACAAAGGGAAGCACUUUCUC - SEQ ID NO: 172 
hsa-miR-525-3p-GAAGGCGCUUCCCUUUAGAGCG - SEQ ID NO: 209 
hsa-miR-526a-CUCUAGAGGGAAGCACUUUCUG - SEQ ID NO: 173 
hsa-miR-549-UGACAACUAUGGAUGAGCUCU- SEQ ID NO: 174 
hsa-miR-558-UGAGCUGCUGUACCAAAAU ·SEQ ID NO 225 
hsa-miR-578-CUUCUUGUGCUCUAGGAUUGU - SEQ ID NO: 175 
hsa-miR-611-GCGAGGACCCCUCGGGGUCUGAC- SEQ ID NO: 176 
FIG. 3 
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hsa-miR-34a-UGGCAGUGUCUUAGCUGGUUGU - SEQ ID NO: 177 
has-miR-124a-UAAGGCACGCGGUGAAUGCC - SEQ ID NO: 178 
hsa-miR-195-UAGCAGCACAGAAAUAUUGGC- SEQ ID NO: 50 
hsa-miR-372-AAAGUGCUGCGACAUUUGAGCGU - SEQ ID NO: 179 
hsa-miR-502-3p-AAUGCACCUGGGCAAGGAUUCA - SEQ ID NO: 180 
hsa-miR-502-5p-AUCCUUGCUAUCUGGGUGCUA- preferred - SEQ ID NO: 181 
hsa-miR-521-AACGCACUUCCCUUUAGAGUGU - SEQ ID NO: 182 
hsa-miR-568-AUGUAUAAAUGUAUACACAC - SEQ ID NO: 183 
hsa-miR-575-GAGCCAGUUGGACAGGAGC - SEQ ID NO: 184 
FIG. 4 
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hsa-miR-10a-UACCCUGUAGAUCCGAAUUUGUG - SEQ ID NO 185 
hsa-miR-137-UUAUUGCUUAAGAAUACGCGUAG- SEQ ID NO: 186 
hsa-miR-205-UCCUUCAUUCCACCGGAGUCUG - SEQ ID NO: 187 
hsa-miR-206-UGGAAUGUAAGGAAGUGUGUGG- SEQ ID NO: 188 
hsa-miR-208a-AUAAGACGAGCAAAMGCUUGU - preferred - SEQ ID NO: 189 
hsa-miR-208b-AUAAGACGAACAAAAGGUUUGU - SEQ ID NO: 190 
hsa-miR-216b-AAAUCUCUGCAGGCAAAUGUGA - SEQ ID NO: 191 
hsa-miR-216a-UAAUCUCAGCUGGCAACUGUGA- preferred - SEQ ID NO: 192 
hsa-miR-302a-UAAGUGCUUCCAUGUUUUGGUGA - SEQ ID NO: 193 
hsa-miR-302b 0 -ACUUUAACAUGGAAGUGCUUUC - SEQ ID NO: 194 
hsa-miR-302c-UAAGUGCUUCCAUGUUUCAGUGG- SEQ ID NO: 195 
hsa-m1R-302c0 -UUUAACAUGGGGGUACCUGCUG - SEQ ID NO: 196 
hsa-miR-346-UGUCUGCCCGCAUGCCUGCCUCU - SEQ ID NO. 197 
hsa-miR-383-AGAUCAGAAGGUGAUUGUGGCU - SEQ ID NO: 198 
hsa-miR-498-UUUCAAGCCAGGGGGCGUUUUUC - SEQ ID NO 199 
hsa-miR-499-5p-UUAAGACUUGCAGUGAUGUUU - preferred - SEQ ID NO: 200 
hsa-miR-499-3p-AACAUCACAGCAAGUCUGUGCU - SEQ ID NO: 201 
has-miR-509-3p-UGAUUGGUACGUCUGUGGGUAG - SEQ ID NO: 202 
hsa-miR-510-UACUCAGGAGAGUGGCAAUCAC - SEQ ID NO: 203 
hsa-miR-515-5p-UUCUCCAAAAGAAAGCACUUUCUG- SEQ ID NO: 204 
hsa-miR-518c0 -UCUCUGGAGGGAAGCACUUUCUG- SEQ ID NO: 205 
hsa-miR-519b-3p-AAAGUGCAUCCUUUUAGAGGUU - preferred - SEQ ID NO: 206 
hsa-miR-5191:>-Sp-CUCUAGAGGGAAGCGCUUUCUG - SEQ ID NO 207 
hsa-miR-520d-3p-AAAGUGCUUCUCUUUGGUGGGU - SEQ ID NO: 170 
hsa-miR-520d-5p-CUACAAAGGGAAGCCCUUUC - SEQ ID NO: 169 
hsa-miR-525-5p-CUCCAGAGGGAUGCACUUUCU - preferred • SEQ ID NO: 208 
hsa-miR-525-3p-GAAGGCGCUUCCCUUUAGAGCG - SEQ ID NO: 209 
has-miR-526b-CUCUUGAGGGAAGCACUUUCUGU - SEQ ID NO: 210 
hsa-miR-548b-3p-CAAGAACCUCAGUUGCUUUUGU - preferred - SEQ ID NO: 211 
hsa-miR-5481:>-Sp-AAAAGUAAUUGUGGUUUUGGCC ·SEQ ID NO: 212 
hsa-miR-551a-GCGACCCACUCUUGGUUUCCA- SEQ ID NO: 213 
hsa-miR-553-AAAACGGUGAGAUUUUGUUUU - SEQ ID NO: 214 
hsa-mlR-577-UAGAUAAAAUAUUGGUACCUG - SEQ ID NO 215 
hsa-miR-600-ACUUACAGACAAGAGCCUUGCUC - SEQ ID NO: 216 
hsa-miR-604-AGGCUGCGGAAUUCAGGAC - SEQ ID NO 217 
hsa-miR-606-AAACUACUGAAAAUCAAAGAU - SEQ ID NO: 218 
hsa-miR-643-ACUUGUAUGCUAGCUCAGGUAG- SEQ ID NO: 219 
hsa-miR-647-GUGGCUGCACUCACUUCCUUC- SEQ ID NO: 220 
hsa-rniR-658-GGCGGAGGGMGUAGGUCCGUUGGU - SEQ ID NO: 221 
hsa-miR-802-CAGUAACAAAGAUUCAUCCUUGU - SEQ ID NO: 222 
hsa-miR-516a-5p-UUCUCGAGGAAAGAAGCACUUUC - SEQ ID NO: 223 
hsa-miR-555-AGGGUAAGCUGAACCUCUGAU • SEQ ID NO: 224 
hsa-miR-558-UGAGCUGCUGUACCAAAAU - SEQ ID NO: 225 
hsa-miR-569-AGUUAAUGAAUCCUGGAAAGU - SEQ ID NO: 226 
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1 
METHOD FOR DETERMINING THE ORIGIN 
OF A SAMPLE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
identify the species of origin. Therefore these methods are 
costly not only in the time and labor required fortheir comple-
tion, but also in terms of the amount of sample consumed 
during the performance of each assay. While these conven-
tional methods can confirm the presence of human blood and 
semen, none of the routinely used serological and immuno-
logical tests can definitely identify the presence of human 
saliva or vaginal secretions. With the large volume of cases 
that operational crime laboratories are faced with processing 
The present application is a U.S. National Stage Applica-
tion under35 U.S.C. §371 oflntemational PatentApplication 
No. PCT/EP2009/005254, filed Jul. 20, 2009, which claims 
benefit of U.S. Provisional Patent Application No. 61/082, 
056, filed Jul. 18, 2008. 
SEQUENCE LISTING 
10 every year, a significant amount of the total time spent on an 
individual case can be devoted solely to the screening of 
evidentiary items for the presence of biological materials. 
The inability to positively confirm the presence of certain 
biological fluids, the consumption of valuable samples and 
The instant application contains a Sequence Listing which 
has been submitted via EFS-Web and is hereby incorporated 
by reference in its entirety. Said ASCII copy, created on Jan. 
15 the time and labour required has resulted in a trend to bypass 
conventional body fluid identification methods and proceed 
straight to the analysis of DNA present in forensic samples. 
18, 2011, is named Sequence_listing.txt and is 33, 798 byte in 
size. 
There are several disadvantages to bypassing the body fluid 
identification step during bio-molecular forensic analysis. 
The present application pertains to methods and kits for 
determining the nature (e.g. origin) of a sample, e.g. a body 
fluid. The teaching of the present application is particularly 
useful in the field of human identity testing, paternity testing 
or forensic science (forensics). 
20 First, the analytical methods used to analyze DNA are con-
siderably more expensive than basic serological testing. A 
second disadvantage of the disuse of body fluid identification 
methods is that often the identification of the biological mate-
rial present is crucial to the investigation and prosecution of 
25 the case. The application of DNA technology to the biological evi-
dence in criminal casework has revolutionized forensic sci-
ence. The ability to identify, with a high degree of certainty, a 
suspect in violent crimes now routinely provides valuable 
leads to criminal investigators worldwide, often in circum-
stances where there are no eyewitnesses. Forensic DNA tech- 30 
nology or STR-typing is a very sensitive and universally 
accepted scientific technique. STRs are small DNA regions 
that contain DNA segments that repeat several times in tan-
dem. Repeated sequences are a fundamental feature of 
genomes and play an important role in genomic fingerprint- 35 
ing (for review see Jobling and Gill, Nature Reviews in 
Genetics, Vol. 5, pp 739; 2004). 
Human identity DNA testing involves generating informa-
tion on the size and number of certain repetitive sequences. 
This information resembles the unique pattern of a fingerprint 40 
and is thus often referred to as the "genetic fingerprint" of a 
human individual. Genetics fingerprints may be compared 
with each other in a database system and allow for positive 
identification of an individual. 
The routine use of body fluid identification methods prior 
to DNA analysis awaits the development of suitable molecu-
lar genetics based methods that are fully compatible with the 
current DNA analysis pipeline. In order for any new body 
fluid assay to be suitable for forensic casework it must dem-
onstrate a high degree of specificity for each body fluid, 
permit parallel analysis of the different biological fluids, be 
completed in a timely and labour efficient manner and must 
be sufficiently sensitive. 
It is thus the object of the present invention to provide a 
method which allows determining the nature of a sample, 
such as a forensic sample. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows Table 1 which depicts suitable miRNAs 
which are useful markers for blood. 
FIG. 2 shows Table 2 which depicts suitable miRNAs 
which are useful markers for menstrual blood. 
FIG. 3 shows Table 3 which depicts suitable miRNAs 
which arc useful markers for semen. 
FIG. 4 shows Table 4 which depicts suitable miRNAs 
which are useful markers for vaginal secretions 
However, genetic fingerprints do not reveal any informa- 45 
tion on the physical appearance of the human donor--except 
for the sex---or the specific nature and origin of the human 
sample. However, such information is very useful in criminal 
investigation as it can make a decisive difference whether a 
sample obtained from the clothing of a sexual assault victim 
FIG. 5 shows Table 5 which depicts suitable miRNAs 
50 which are useful markers for saliva. 
is a droplet of sperm or saliva, or whether blood sampled from 
some female underwear is peripheral or menstrual blood. 
FIG. 6 shows the results of a miRNA candidate screening 
using pooled body fluid samples. 
FIG. 7A-7E show the development of 2-1) miRNA body 
fluid identification assays. 
FIG. 8 shows the stability of miRNA expression even in 
environmentally compromised. 
FIG. 9 shows the generation of mature miRNAs according 
to one assumed embodiment. 
According to one embodiment, a method for determining 
Conventional methods for the identification of different 
body fluids like blood, semen and saliva from biological 
stains involve immunological or enzymatic detection of cer- 55 
tain proteins, which are characteristic for the respective 
sample. However, these technologies (e.g. ELISA, lateral 
flow chromatography) are often not sensitive enough for 
forensic investigation as proteins camiot be amplified and 
forensic stains often contain only minute amounts of materi-
als. 
60 the nature of a sample is provided, wherein the presence or 
absence of at least one marker small non-coding RNA in the 
sample is detected. The detection of a respective marker small 
non-coding RNA allows the identification of the nature of the 
sample, such as e.g. its origin or type. The analysis/detection 
Typically, such conventional methods for body fluid stain 
analysis are carried out in a serial mamier, with a portion of 
the stain being tested for only one body fluid at a time. 
Frequently multiple tests are required to first presumptively 
identify the presence of biological fluids followed by addi-
tional testing in order to confirm the presence of the fluid or 
65 of the expression of at least one small non-coding RNA is 
advantageous over conventional detection methods which 
e.g. target mRNA, which is likely to be more susceptible to 
US 8,936,909 B2 
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degradation and expected to be less stable due to its larger 
size. It is also advantageous over the detection of marker 
proteins due to the reasons outlined above. However, respec-
tive methods can also be used in combination with the method 
of the present invention. 
Several small non-coding RNAs (ncRNAs) are known in 
the prior art. They comprise infrastructural ncRNAs such as, 
for example, tRNAs, rRNAs, spliceosomal uRNAs or snR-
NAs and the common snoRNAs. Both translation and splic-
ing require core infrastructural RNAs not only for sequence-
specific recognition of RNA substrates, but also for the 
catalytic process itself. A further category of small non-cod-
ing RNAs comprises small regulatory ncRNAs such as snoR-
NAs and miRNAs/siRNAs. 
snoRNAs generally range from 50 to 300 nucleotides in 
length and guide the side-specific modification of nucleotides 
and target RNAs via short regions of base paring. There are 
two major classes, the box CID snoRNAs which guide 2'-0-
ribose-metylation and the box HI ACA snoRNAs which guide 
pseudouridylation of target RNAs. At least some snoRNAs 
exhibit tissue-specific and developmental regulation and/or 
imprinting, indicative of a regulatory function. 
4 
nature of a sample, e.g. in forensic testing due to several 
reasons. Because of their small size they are generally 
expected to be more stable than larger RNA species and in 
particular mRNA. In addition they are typically expressed at 
very high rates. Thus, they potentially can also be recovered 
from older samples what is of particular importance in the 
field of forensics. Furthermore, their regulatory function in 
gene expression during human development and tissue dif-
ferentiation suggests the potential for identification of spe-
10 cific miRNA species that are indicative of the nature of a 
sample or even the donor's physical status such as age or 
health. To date more than 500 different individual miRNA 
and other small RNAs have been identified in humans. The 
identification of miRNAs which are specifically expressed in 
15 a particular sample type provides a valuable marker for 
sample typing. 
According to one embodiment, the presence or absence of 
at least two marker small-non-coding RNAs in the sample is 
detected in order to determine the nature of the sample. To 
20 characterise the sample type (e.g. to determine whether a 
sample is semen or saliva) by using at least two sample 
specific markers provides more security during testing and 
allows a more reliable interpretation/control of the results. miRNAs and siRNAs are short, approximately less than 30 
and usually around 22 nucleotides long RNA molecules 
derived either from hairpin or double stranded RNA precur-
sors. Details of miRNA and siRNA biology and their bio-
chemistry are known in the prior art. miRNAs suppress trans-
lation via non-perfect pairing with target mRNAs-usually 
involving a seed pairing of just 6-8 nucleotides in length or (as 
with siRNAs) cause degradation of target RNAs via the RISC 30 
complex in the case of perfect complementarily with the 
target site-the phenomenon known as RNAi. It is estimated 
that approximately 113 of human protein-coding genes are 
controlled by miRNAs. In addition, siRNAs derived from 
repeats participate in the establishment of silenced (hetero- 35 
chromatic) chromatin, as well as in other aspects of chromo-
some dynamics. miRNAs are derived from the intrans and 
exons of both protein-coding and non-coding transcripts that 
are synthesised by RNA polymerase II. It has recently been 
shown that a number of mammalian miRNAs are derived 40 
A specifically suitable marker small non-coding RNA has 
25 at least one of the following characteristics: 
a. It is expressed in the particular sample for which the 
small non-coding RNA serves as marker; 
b. it shows a discriminating/differential expression pattern 
in a particular type of sample compared to other sample 
types; 
c. it is specifically expressed in a particular sample type; 
and/or 
d. it is expressed in higher abundance in a particular sample 
type. 
A respective expression pattern which is characteristic for 
a particular sample type and differs from the expression pat-
tern in other (either all, or at least some) sample types ensures 
sufficient specificity for the sample type for which the respec-
tive small non-coding RNA is used as a marker. Appropriate 
differentiation of the expression in the particular type of 
sample compared to other samples is important in order to from repeats, mainly various transposons. Some miRNAs 
also appear to be derived from processed pseudo genes. 
An overview over small non-coding RNAs, their structure 
and function is described in John S. Mattick and Igor V. 
Makunin: Non-coding RNA, Human Molecular Genetics 
2006, Volume 15, review issue 1Rl7-R29, herein fully incor-
porated by reference. 
According to one embodiment the small non-coding RNA 
is a miRNA. In the last few years, the identification of 
microRNA (miRNA) and the recognition ofits important role 
in regulation of gene expression have led to increasing inter-
est in the identification and characterization of miRNAs 
(Cummins, J.M. andVelculescu, V. E. (2006) Implications of 
micro-RNA profiling for cancer diagnosis. Oncogene 25, 
6220; microRNAs supplement (2006) Nature Genetics 38, 
6s; Kloosterman, W. P. and Plasterk, R. H. (2006) The diverse 
functions of microRNAs in animal development and disease. 
Dev. Cell 11, 441. A growing body of evidence suggests that 
miRNAs play a role in many diverse biological processes 
such as development, differentiation, and apoptosis. Mis-
regulation of miRNA expression is reported to be associated 
with several cancers and other diseases. MicroRNAs (miR-
NAs) are small non-coding RNAs, which usually have a 
length of less than 30 nt, usually around 21 to 22 nt. The 
generation ofmiRNAs is also described in FIG. 9. 
miRNAs and other small non-coding RNAs such as snoR-
NAs or piRNAs are ideal assay targets for identifying the 
enhance the specificity of the determination method. It is 
advantageous to use a marker small non-coding RNA which 
is expressed in the particular sample. This, as the detection of 
45 an expression ensures that the assay worked properly. In case 
a marker small non-cording RNA is used whose characteristic 
is that it is not expressed in a certain sample type, there is 
always a certain risk/doubt that the method/assay did not 
work properly which would need to be ensured by using 
50 appropriate controls. The use of a high-abundance small non-
coding RNA over a low-abundance small non-coding RNA is 
generally preferred, as the expression of a high-abundance 
marker is easier to detect. 
Typical sample types that play an important role in particu-
55 lar in the field of forensics are e.g. blood, menstrual blood, 
semen, vaginal secret and saliva. The method of the present 
invention allows a reliable identification/determination of the 
type of the respective sample by detecting/analysing the 
expression pattern of respective marker small non-coding 
60 RNAs. The detection of the expression of a specific marker or 
a certain marker profile characteristic for the specific sample 
allows the identification of the nature/origin of the sample 
(e.g. whether it is semen or saliva). It is also within the scope 
of the present invention to detect the presence or absence of a 
65 plurality of small non-coding RNAs indicative as markers for 
a plurality of different sample types, and determining the 
nature of the sample based on the obtained expression profile 
US 8,936,909 B2 
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for the respective markers. E.g. in case a sample is collected 
at a forensic scene that could be blood, one could simulta-
neously or consecutively perform the method of the present 
application by analysing the expression of marker small non-
coding RNAs for blood and menstrual blood. Depending on 
the obtained expression profile, one would obtain the infor-
mation whether the collected sample is peripheral blood or 
menstrual blood. The principle is also valid for other sample 
types such as the ones mentioned above. The marker small 
non-coding RNAs for different tissues may also be tested in 10 
parallel and thus in one assay thereby allowing the typing of 
the unidentified sample. 
For detecting the marker small non-coding RNA in the 
sample, any detection method can be used. It is preferred that 
15 
the detection method also allows a quantification of the 
detected marker small non-coding RNA in the sample. 
Hence, the detection is preferably quantitative. Non-limiting 
examples of suitable detection methods are amplification, 
PCR, real time PCR, e.g. using SybrGreen or probes, isother-
20 
ma! amplification reactions, sequencing reactions, in particu-
lar pyrosequencing and massive parallel high throughput 
sequencing (for example 454 sequencing, Applied Biosys-
tems SOLID which also allows a quantification), detection 
based on hybridisation techniques, e.g. via microarrays, 
25 
chips, bead arrays, functionalised surfaces, e.g. using micro-
titer plates, and detection via high resolution melt curve 
analysis. The detection may comprise the use of labelled 
probes/oligonucleotides, for example fluorescently labelled 
oligonucleotides or amplification products. Other detectable 
30 
signals are based e.g. on chemiluminescence, radioactivity or 
electrochemical processes. Several suitable detection meth-
ods are known in the prior art that can be used in conjunction 
with the present invention which thus do not need to be 
described in detail herein. Suitable methods are also 
35 















It was demonstrated in extensive experiments by the inven-
tors that the respective miRNAs are useful markers for blood, 
particularly peripheral blood, which thus allow the secure 
identification/determination of an unknown sample as a 
respective blood sample. Particularly advantageous are the 
use of Let7i, miR16, miR451, and/or miR15b as specific 
markers. Preferably, at least miR451 andmiR16 are used as a 
marker pair respectively marker combination for typing 
peripheral blood samples. 
In addition or alternatively, at least one small non-coding 
RNA is detected which comprises or consists of a sequence 
selected from the group of small non-coding RNAs listed in 
Table 2 (see FIG. 2) or is an isoform thereof (having no more 
than 5, preferably no more than 3 or more preferred no more 
than 2 base changes) or is derived from the same premiRNA 
as the respective small non-coding RNAs listed in Table 2 (see 
FIG. 2), as a marker for menstrual blood. The respective 
miRNAs are specifically/differentially expressed in blood 
samples and in particular in menstrual blood samples and are 
thus suitable markers for determining/identifying an 
unknown sample as a menstrual blood sample. Suitable 
sequence specific oligonucleotides and probes that are useful 
for amplifying and/or detecting the corresponding marker 
miRNAs can be designed applying known principles e.g. 
based on the shown sequence of the miRNA; sequence spe-
cific oligonucleotides and probes should be at least 80% 
According to one embodiment, at least one small non-
coding RNA is detected which comprises or consists of a 
sequence selected from the group of small non-coding RNAs 
listed in Table 1 (see FIG. 1) or is an isoform thereof (having 
no more than 5, preferably no more than 3 or more preferred 
40 
homologous, preferably more than 90% complementary to 
the target sequences to allow sequence specific detection. It is 
advantageous that at least two small non-coding RNAs are 
selected from the following group of small non-coding RNAs 
as markers: 
no more than 2 base changes) or is derived from the same 
premiRNA as the respective small non-coding RNAs listed in 
Table 1 (see FIG. 1), as a marker for blood, in particular 
45 
peripheral blood. The respective miRNAs are specifically/ 
differentially expressed in blood samples and are thus suit-
able markers for determining/identifying an unknown sample 
as a blood sample. Suitable sequence specific oligonucle-
otides and probes that are useful for amplifying and/or detect-
50 
ing the corresponding marker miRNAs can be designed 
applying known principles e.g. based on the shown sequence 
of the miRNA; sequence specific oligonucleotides and probes 
should be at least 80% homologous, preferably at least 90% 
complementary to the target sequence to allow sequence spe-
55 
cific detection. It is advantageous that at least two small 
non-coding RNAs are selected from the following group of 






























Particularly suitable are the detection of the following 
65 miRNAs as markers for menstrual blood: miR451, miR423, 
miR484, miR412, miR425-3p and/or miR452*. It was dem-
onstrated in extensive experiments by the inventors that the 
US 8,936,909 B2 
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respective miRNAs are useful markers for menstrual blood 
which thus allow the secure identification/determination of 
an unknown sample as a menstrual blood sample even com-
pared to a peripheral blood sample. Particularly suitable is the 
use of at least miR412 and miR451 as marker pair respec-
tively combination for typing menstrual blood samples. The 
respective markers also allow a differentiation between men-
strual blood and peripheral blood samples. 
8 
than 5, preferably no more than 3 or more preferred no more 
than 2 base changes) or is derived from the same premiRNA 
as the respective small non-coding RNAs listed in Table 4 (see 
FIG. 4), as a marker for vaginal secretions. The respective 
miRNAs are specifically/differentially expressed in vaginal 
secretion samples and are thus suitable markers for determin-
ing/identifying an unknown sample as a vaginal secretion 
sample. Suitable sequence specific oligonucleotides and 
probes that are useful for amplifying and/or detecting the 
corresponding marker miRNAs can be designed applying The detection of menstrual blood markers in combination 
with general and/or peripheral blood markers (see above) is 
particularly useful for a blood/menstrual blood assay. As the 
menstrual blood markers also show a differential expression 
pattern in peripheral blood compared to menstrual blood, they 
can also be used in order to distinguish peripheral blood from 
menstrual blood samples. 
10 known principles e.g. based on the shown sequence of the 
miRNA, oligonucleotides shall be at least 80% homologous, 
preferably at least 90% complementary to the target 
sequences to allow sequence specific detection. It is advanta-
geous that at least two small non-coding RNAs are selected 
15 from the following group of small non-coding RNAs as mark-
ers for vaginal secretion samples: 
In addition or alternatively, at least one small non-coding 
RNA is detected which comprises or consists of a sequence 
selected from the group of small non-coding RNAs listed in 
Table 3 (see FIG. 3) or is an isoform thereof (having no more 
than 5, preferably no more than 3 or more preferred no more 20 
than 2 base changes) or is derived from the same premiRNA 
as the respective small non-coding RNAs listed in Table 3 (see 
FIG. 3), as a marker for semen. The respective miRNAs are 
specifically/differentially expressed in semen samples and 
are thus suitable markers for determining/identifying an 25 
unknown sample as a semen sample. Suitable sequence spe-
cific oligonucleotides and probes that are useful for amplify-
ing and/or detecting the corresponding marker miRNAs can 
be designed applying known principles e.g. based on the 
shown sequence of the miRNA; sequence-specific oligo- 30 
nucleotides and probes should be at least 80% homologous, 
preferably at least 90% complementary to the target 
sequences to allow sequence-specific detection. It is advan-
tageous that at least two small non-coding RNAs are selected 
from the following group of small non-coding RNAs as mark- 35 






It was demonstrated in extensive experiments by the inven-
tors that the respective miRNAs are particularly useful mark-
ers for vaginal secretions which thus allow the secure identi-
fication/determination of an unknown sample as a vaginal 
secretion sample. Particularly suitable are the detection of the 
following miRNAs as markers for vaginal secretions: 
miR124a, miR195, and/or miR372. Particularly suitable is 
the use of at least miR124a, miR372, and miR195 as marker 
pair respectively marker combination for typing/identifying 
vaginal secretion samples. 
Additionally or alternatively, at least one small non-coding 
RNA is detected which comprises or consists of a sequence 
selected from the group of small non-coding RNAs listed in 
Table 5 (see FIG. 5) or is an isoform thereof (having no more 
than 5, preferably no more than 3 or more preferred no more 


















as the respective small non-coding RNAs listed in Table 5 (see 
FIG. 5), as a marker for saliva. The respective miRNAs are 
specifically/differentially expressed in saliva samples and are 
thus suitable markers for determining/identifying an 
unknown sample as a saliva sample. Suitable sequence spe-
cific oligonucleotides and probes that are useful for amplify-
45 ing and/or detecting the corresponding marker miRNAs can 
be designed applying known principles e.g. based on the 
shown sequence of the miRNA. It is advantageous that at least 
two small non-coding RNAs are selected from the following 
group of small non-coding RNAs as markers for saliva: 
50 
It was demonstrated in extensive experiments by the inven-
tors that the respective miRNAs are particularly useful mark- 55 
ers for semen which thus allow the secure identification/ 
determination of an unknown sample as a semen sample. 
Particularly suitable are the detection of the following miR-
NAs as markers for semen: miRlOb, miR135b, miR517a, 
miR508, miR514, miR520g/h and/or miR204. Particularly 60 
suitable is the use of at least miR135b and miRl Ob as marker 
pair respectively marker combination for typing/identifying 
semen samples. 
Alternatively or additionally, at least one small non-coding 
RNA is detected which comprises or consists of a sequence 65 
selected from the group of small non-coding RNAs listed in 

















It was demonstrated in extensive experiments by the inven-
tors that the respective miRNAs are particularly specific 
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For absolute quantification, e.g. a synthetic miRNA can be 
used that can be mixed for more reliable handling or mimic of 
background nucleic acid with carrier RNA such as corn or 
bacterial RNA. E.g. 50 ng per RT reaction (2.5 ng/µl) of the 
carrier can be used. A respective approach enables maximum 
quantification of all steps including the reverse transcriptase 
step (see below) with minimum effort. 
markers for saliva which thus allow the secure identification/ 
determination of an unknown sample as a saliva sample. 
Particularly suitable are the detection of the following miR-
NAs as markers for saliva: miR658, miR606, miR510, 
miR526b, miR208 and/ormiR205. Particularly suitable is the 
use of at least miR658 and miR205 as marker pair respec-
tively marker combination for typing/identifying saliva 
samples. It was demonstrated in extensive experiments by the 
inventors that the respective miRNAs are particularly useful 
markers for saliva which thus allows the secure identification/ 
determination of an unknown sample as a saliva sample. 
Another normalisation approach which can be used to 
quantify the marker small non-coding RNAs and in particular 
10 the miRNAs is the delta delta Ct method. For relative delta 
The success and accuracy of any biological assay involving 
the use of quantitative expression analysis often also depends 
delta Ct quantification, assays for snoRNAs can be used. A 
snoRNA with a Ct value close to the marker small non-coding 
RNA of interest is an appropriate one as control. Alterna-
tively, if individual expression levels are not determined, e.g. on proper normalization of data. The purpose of normaliza-
tion is to minimize potential variation that can mask or exag-
gerate biologically meaningful changes. Quantitative assess-
ments of total RNA in a sample can be affected by various 
factors including extraction efficiencies of RNA from differ-
ent body fluids and substrates upon which they were depos-
ited as well as potential RNA degradation. The currently 
available RNA quantification methods are usually not 
human-specific and therefore RNA quantity estimations can 
also be affected by the presence of contaminating non-human 
species. Potential normalization strategies for use in miRNA 
expression analysis include the use of housekeeping genes 
(mRNA), small RNAs such as 5S rRNA or U6b (a small 
nucleolar RNA), and universally expressedmiRNAs. Ideally, 
15 the snoRNAs U6B and U44 can be used as a general control 
for all small non-coding RNAs and in particular miRNAs. 
Small nucleolar RNAs ( snoRNAs) participate in the process-
ing and modification of other ribonucleic acids-in particular 
rRNA. snoRNAs do not encoded proteins but operate as 
20 "guide" RNAs, by directing catalytically active proteins to 
the right places/positions of the RNA. Usually, snoRNAs are 
in the cell associated with other proteins and form a so-called 
snoRNPs (small nucleolar ribonucleoprotein particle). The 
modifications that are introduced by the snoRNPs into the 
25 rRNAs are inter alia essential for the functions of the ribo-
a normalizer should be present in relatively high and consis-
tent abundance in all tissues or cell types, should be of similar 
size and found in similar cellular environments as the target 30 
molecule, and be compatible with the analysis methods uti-
lized for the target molecule. Messenger RNAs from house-
keeping genes may not be the most suitable targets for nor-
malization of miRNA expression data due to abundance, 
degradation rates and amplimer size differences. For 35 
example, universally (and approximately) equally expressed 
'housekeeping' miRNAs could be used as normalizers. 
Thus, according to one embodiment, the expression of the 
marker small non-coding RNA is normalized relative to a 
generically expressed small non-coding RNA which can be of 40 
the same or a different type than the marker sample. This 
allows a relative quantification of the marker small non-cod-
ing RNA and hence ensures a reliable detection independent 
of extraction efficiency and sample preservation. The normal-
ization marker may serve as a positive control at the same 45 
time. According to one embodiment, the expression of a small 
non-coding RNA is determined for normalisation which is 
different from the marker small non-coding RNA to be 
detected. To detect a small non-coding RNA for normalisa-
tion is advantageous as they would depict the same degrada- 50 
tion profile/advantages as the small non-coding RNA 
detected as a marker for a particular sample type. The small 
non-coding RNA used for normalization has a Ct value close 
some. 
According to one embodiment, total RNA extracts are first 
quantitated e.g. using a RiboGreen fluorescence assay and 
equal amounts of total RNA are used in subsequent reverse 
transcription assays. However, this normalization strategy 
may not be sufficiently precise enough on its own for certain 
applications of the present technology due the potential pres-
ence of differing levels of non-human sources of RNA in 
some forensic samples (e.g. bacteria in saliva and vaginal 
secretions). Therefore, one may also employ alternatively or 
additionally a delta Ct (deltaCt) metric which measures the 
relative abundance of a particular miRNA in relation to e.g. a 
small nucleolar RNA, e.g. U6b or U44. U6b is advantageous 
due to its high abundance and apparent stability in different 
body fluid stains of forensic interest. For example, for high 
abundance miRNA candidates whose expression was greater 
than e.g. U6b, the deltaCt metric was obtained by subtracting 
the Ct value of miRNA from the Ct value of the U6b, whereas 
for miRNAs present in lower abundance than U6b, the 
deltaCt was obtained by subtracting the Ct value of e.g. U6b 
from the Ct value of the miRNA. 
According to one embodiment, the method comprises at 
least one of the following steps: 
a. isolating RNA from the sample 
b. optionally quantifying the isolated RNA 
c. reverse transcribing the isolated RNA 
d. detecting, preferably amplifying, at least one marker 
small non-coding RNA. 
The respective process steps are routine steps for the per-to the marker small non-coding RNA in order to simplify the 
comparison. 
According to one embodiment, the small non-coding RNA 
used for normalization is selected from the group consisting 
ofU6B, U44, Sl 5 or miRNAs which have a similar Ct value 
in the samples of interest. The respective small non-coding 
RNAs showed good characteristics in the performed tests. 
Other examples include U26, U27, U28, U29, U30, U31, 
U38B, U43, U48 and U90. The choice of the normaliser may 
also be adapted to the sample type or assay as it may provide 
further sample specificity (see below). Also more than one 
normaliser may be used. 
55 son of skill in the art and thus can be easily and routinely 
performed. Amplification is preferably performed by PCR in 
order to be able to detect the presence or absence of the 
marker small non-coding RNAs even in very small samples. 
Suitable amplification and detection methods are described 
Different normalisation concepts can be used according to 
the present invention. 
60 above. The detection is preferably quantitative. 
Isolation of the RNA is performed by using conventional 
methods. Preferably methods are used which allow the effi-
cient isolation of small RNAs of e.g. less than 1000 or even 
500 or 100 nucleotides from a sample. One suitable method is 
65 the standard guanidine isothiocyanate-phenol: chloroform 
based extraction method (see e.g. Chomczynski P, Sacchi N 
(1987) Single-step method of RNA isolation by acid guani-
US 8,936,909 B2 
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dinium thiocyanate-phenol-chloroform extraction. Anal Bio-
chem 162: 156-159). Numerous non-organic, silica-based 
extraction kits are now commercially available for the recov-
ery of miRNAs and, in contrast to the phenol-chloroforms 
methods, are easily transferable to an automated platform. 
Thus these kits may prove more suitable for use in forensic 
casework. An appropriate amount of total RNA (e.g. -1-5 ng) 
would be used for reverse transcription (RT). Several reverse 
transcription methods are known in the prior art that can be 
used in conjunction with the present invention. For reverse 10 
transcription, the isolated RNA is preferably tailed (e.g. with 
a poly A tail) in order to allow the reverse transcription of the 
small non-coding RNA by using a universal oligonucleotide/ 
adapter recognising the tail. Amplification is performed using 
appropriate oligonucleotides. E.g. a sequence specific oligo- 15 
nucleotide for the marker small non-coding RNA of interest 
and a oligonucleotide recognising the tail/adapter incorpo-
rated due to the tailing/reverse transcription can be used for 
amplification. Suitable commercially available kits for 
extraction and reverse transcription are e.g. sold by QIAGEN, 20 
such as e.g. the miScript system. Unlike other commercially 
available miRNA systems that employ miRNA-specific 
reverse transcription strategies, the miScript system allows 
cDNA to be produced from all RNA species within the 
sample, including mRNAs and other small non-coding 25 
RNAs. This could be advantageous in forensic casework 
where multiple individual reverse transcription reactions 
required to analyze a sufficient amount of miRNAs may not 
be possible due to a limited amount of genetic material recov-
ered from most evidentiary items. 30 
The ability to simultaneously reverse transcribe other RNA 
species, such as mRNAs, may also be useful if parallel assays 
need to be performed for the detection of tissue specific 
mRNAs or housekeeping genes. Suitable methods are also 
described in WO 2008/020008, herein incorporated by refer- 35 
ence. An appropriate volume of the RT product to obtain e.g. 
50 pg (suitable for the blood, saliva, vaginal secretions and 
menstrual blood assays) or e.g. 500 pg (suitable forthe semen 
assay) cDNA would be used in the miRNA quantitative real 
time PCR (QT-PCR) assay which, according to one embodi- 40 
ment, uses the miScript SYBR Green PCR system and a 
miRNA specific oligonucleotide. Suitable sequence specific 
oligonucleotides and probes that are useful for amplifying 
and/or detecting the corresponding marker small non-coding 
RNAs, e.g. miRNAs can be designed applying known prin- 45 
ciples based on the sequence of the marker miRNA to be 
detected. 
According to the method/assay of the present invention, it 
is possible to analyse several marker small non-coding RNAs 
and if desired, at least one, preferably at least two, normalis- 50 
ers (e.g. U6b and U44) from a single RT product. Numerous 
RT reactions are not required for the examination of multiple 
marker small non-coding RNAs in the same sample. If a 
real-time PCR is performed, the Ct values for each marker 
small non-coding RNA may then be evaluated to ensure all 55 
obtained values are within acceptable ranges. All acceptable 
expression data can then be normalized using e.g. U6b in 
which the Ct value of the miRNA is subtracted from the Ct 
value ofU6b. The delta Ct values for the at least two marker 
12 
mine the species of origin. The presence of human (or higher 
primate) blood would be indicated by the presence of the 
unknown sample within the cluster of human blood samples. 
It was shown by experiments, that the U44-normalized assay 
can be used to identify the presence of human or higher 
primate blood if a positive result for an unknown sample was 
obtained using the U6b-normalized blood assay. Thus, the 
choice of the right normalizer may provide species specific-
ity. 
The method/assay according to the present invention suc-
cessfully detected the presence of biological material in aged 
and environmentally compromised samples as well as in 
simulated casework samples that included admixed body 
fluid samples, post coital samples and trace body fluid 
samples and is thus a valuable tool for identifying unknown 
sample types. As is outlined above, the method/assay of the 
present application is particularly useful for the determina-
tion/identification of forensic samples, and in particular of 
samples of small quantity. The method/assay can also be used 
in combination with conventional methods for identifying the 
nature of a sample, e.g. with methods which detect mRNA 
targets as markers in order to identify the nature of a sample 
types. 
Also provided is a method for identifying at least one small 
non-coding RNA as a marker for a particular sample type, 
comprising at least the following steps: 
a. determining the expression of at least one candidate 
small non-coding RNA in different sample types; 
b. selecting at least one small non-coding RNA that is 
differentially expressed in a particular sample type as 
marker small non-coding RNA for said sample type. 
A respective screening/identification method allows the 
identification of further small non-coding RNAs that can be 
used as markers for different samples, such as tissue and body 
fluid samples. The sample can be selected from any human 
body fluid and tissue samples including but not limited to 
blood, menstrual blood, semen, saliva, vaginal secretions, 
skin, brain, lung, testis, adipose, thymus, muscle, spleen, 
placenta, bone marrow, skin, uterus, salivary gland and liver 
and other suitable related materials obvious to those skilled in 
the art. The method is particularly useful for selecting/iden-
tifying a marker small non-coding RNA for determining the 
nature (e.g. origin, tissue type) of a forensic sample. The 
small non-cording RNA that is detected is preferably a mature 
miRNA. Suitable candidates are disclosed in FIGS. 1 to 5. 
It is advantageous regarding specificity and sensitivity that 
the small non-coding RNA selected as marker has at least one 
of the following characteristics: 
a. It is expressed in the particular sample for which the 
small non-coding RNA serves as marker; 
b. it shows a discriminating/differential expression pattern 
in a particular type of sample compared to other sample 
types; 
c. it is specifically expressed in a particular sample type; 
d. it is expressed in higher abundance in a particular sample 
type; and/or 
e. it is expressed in higher abundance in a particular sample 
type than the small non-coding RNA used for normali-
sation and is expressed at lower levels than the small 
non-coding RNA used for normalisation in other sample 
types. 
small non-coding RNAs for each sample/body fluid may then 60 
be used to position the unknown sample e.g. two-dimensional 
scatter plot for each body fluid. The identification of the 
presence of the sample/body fluid would be confirmed ifthe 
unknown sample was found within the cluster of known body 
fluid samples. If a positive result is obtained for e.g. blood, 
delta Ct values using U44 for miR451 and miR16 (preferably 
used in the assay) may then be calculated and used to deter-
In case a Real time PCR is performed, a suitable marker 
small non-coding RNA can be identified by selecting one 
which has a significant lower Ct value in a particular sample 
65 type. 
In order to ensure that the identified small non-coding 
RNAs are the true source of the obtained expression data, 
US 8,936,909 B2 
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reverse transcription negative (RT-) samples, to which no 
reverse transcriptase is added, is evaluated. Preferably, no 
signal is detected in the RT- samples. If a Ct value is, how-
ever, obtained for the RT- samples, for these assays, the Ct 
values should be preferably below the RT- average. 
According to one embodiment the method comprises 
a. Isolating RNA from the sample 
b. optionally quantifying the isolated RNA 
c. reverse transcribing the isolated RNA 
d. detecting, preferably amplifying at least one marker 10 
small non-coding RNA. 
Details are described above; we refer to the above disclo-
sure. 
Also provided is a kit for determining the nature of a 
sample, comprising at least one sequence specific oligonucle- 15 
otide of at least 80% homology, preferably at least 90% 
complementary to the target sequence for detecting the pres-
ence or absence of at least one marker small non-coding RNA 
in a sequence specific marmer. A respective kit allows the easy 
and routine identification of samples and is particularly useful 20 
for forensic applications. The advantages of a respective kit 
are outlined in detail above. Preferably, the small non-coding 
RNA that is detected is a mature miRNA. 
14 
least two small non-coding RNAs are detected which are 
selected from the following group of small non-coding RNAs 




















or an isoform thereof (having no more than 5, preferably no 
more than 3 or more preferred no more than 2 base changes) The kit may comprise oligonucleotides for detecting the 
presence or absence of at least two marker small-non-coding 
RNAs in a sample. As is outlined above, the detection of at 
least two marker small non-coding RNAs increases the reli-
ability of the kit. 
25 and/or a small non-coding RNA derived from the same 
premiRNA. Preferably Let7i, miR16, miR451 and/or 
miR15b, most preferred miR451 and miR16 are detected as 
marker miRNAs. 
Preferably, the marker small non-coding RNA detected by 
the kit has at least one of the following characteristics: 
a. it is expressed in the particular sample for which the 
small non-coding RNA serves as marker; 
b. it shows a discriminating/differential expression pattern 
30 It was demonstrated in extensive experiments by the inven-
tors that the respective miRNAs are particularly specific 
markers for blood which thus allow the secure identification/ 
determination of an unknown sample as a blood sample. 
The kit may comprise additionally or alternatively at least in a particular type of sample compared to other sample 
types; 
c. it is specifically expressed in a particular sample type; 
d. it is expressed in higher abundance in a particular sample 
type; and/or 
e. it has a significant lower Ct value in a particular sample 
type; and/or 
35 one oligonucleotide specific for at least one small non-coding 
RNA selected from the group of small non-coding RNAs 
listed in Table2 (see FIG. 2),preferablymiR412andmiR451, 
or an isoform thereof (having no more than 5, preferably no 
more than 3 or more preferred no more than 2 base changes) 
40 and/or a small non-coding RNA derived from the same 
premiRNA as the respective small non-coding RNAs listed in 
Table 2 (see FIG. 2). A respective specific oligonucleotide is 
preferably at least 80% homologous (identical, respectively 
f. it is expressed in higher abundance in a particular sample 
type than the small non-coding RNA used for normali-
sation and is expressed at lower levels than the small 
non-coding RNA used for normalisation in other sample 
types. 
The advantages are outlined in detail above; we refer to our 
above disclosure. 
45 complementary) to the respective marker target sequence to 
allow sequence specific detection. The respective miRNAs 
are specifically/differentially expressed in menstrual blood 
samples and are thus suitable markers for determining/iden-The kit may comprise at least one sequence specific oligo-
nucleotide for detecting the presence or absence of at least 
one marker small non-coding RNA indicative for a sample 50 
type selected from the group consisting of blood, menstrual 
blood, semen, vaginal secret and saliva. 
The kit may comprise at least one oligonucleotide specific 
for at least one small non-coding RNA selected from the 
group of small non-coding RNAs listed in Table 1 (see FIG. 55 
1), an isoform thereof (having no more than 5, preferably no 
more than 3 or more preferred no more than 2 base changes) 
and/or a small non-coding RNA derived from the same 
premiRNA as the respective small non-coding RNAs listed in 
Table 1 (see FIG. 1). A respective specific oligonucleotide is 60 
preferably at least 80% homologous (identical, respectively 
complementary) to the respective marker target sequence to 
allow sequence specific detection. 
The respective miRNAs are specifically/differentially 
expressed in blood samples and in particular peripheral blood 65 
and are thus suitable markers for determining/identifying an 
unknown sample as a blood sample. It is advantageous that at 
tifying an unknown sample as a menstrual blood sample. It is 
advantageous that at least two small non-coding RNAs are 
selected from the following group of small non-coding RNAs 

























or an isoform thereof (having no more than 5, preferably no 
more than 3 or more preferred no more than 2 base changes) 
and/or a small non-coding RNA derived from the same 
premiRNA. Particularly preferred examples were already 
described above. It was demonstrated in extensive experi-
ments by the inventors that the respective miRNAs are par-
ticularly specific markers for menstrual blood which thus 
allow the secure identification/determination of an unknown 
sample as a menstrual blood sample even compared to a 
peripheral blood sample. 
derived from the same premiRNA as the respective small 
non-coding RNAs listed in Table 4 (see FIG. 4). Preferably 
miR124a, miR372 and miR195 are detected as marker 
miRNA. A respective specific oligonucleotide is preferably at 
least 80% homologous (identical, respectively complemen-
tary) to the respective marker target sequence to allow 
sequence specific detection. Suitable examples for sequence 
specific oligonucleotides are also indicated in Table 4. The 
respective miRNAs are specifically/differentially expressed 
10 in vaginal secretion samples and are thus suitable markers for 
determining/identifying an unknown sample as a vaginal 
secretion sample. It is advantageous that at least two small 
non-coding RNAs are selected from the following group of 
small non-coding RNAs as markers for vaginal secretion 
15 samples: 
The kit may comprise additionally or alternatively at least 
one oligonucleotide specific for at least one small non-coding 20 
RNA selected from the group of small non-coding RNAs 
shown in Table3 (see FIG. 3) or anisoform thereof(havingno 
more than 5, preferably no more than 3 or more preferred no 
more than 2 base changes) and/or a small non-coding RNA 
derived from the same premiRNA as the respective small 25 
non-coding RNAs listed in Table 3 (see FIG. 3), preferably 
miR135b and miRl Ob. A respective specific oligonucleotide 
is preferably at least 80% homologous (identical, respectively 
complementary) to the respective marker target sequence to 
allow sequence specific detection. The respective miRNAs 30 
are specifically/differentially expressed in semen samples 
and are thus suitable markers for determining/identifying an 
unknown sample as a semen sample. It is advantageous that at 
least two small non-coding RNAs are selected from the fol-







or an isoform thereof (having no more than 5, preferably no 
more than 3 or more preferred no more than 2 base changes) 
and/or a small non-coding RNA derived from the same 
premiRNA. It was demonstrated in extensive experiments by 
the inventors that the respective miRNAs are particularly 
specific markers for vaginal secretions which thus allow the 
secure identification/determination of an unknown sample as 
a vaginal secretion sample. 
The kit may comprise additionally or alternatively at least 
one oligonucleotide specific for at least one small non-coding 
RNA selected from the group of small non-coding RNAs 
listed in Table 5 (see FIG. 5), preferably miR658 and miR205 
or an isoform thereof (having no more than 5, preferably no 
more than 3 or more preferred no more than 2 base changes) 
and/or a small non-coding RNA derived from the same 

















40 Table 5 (see FIG. 5). A respective specific oligonucleotide is 
preferably at least 80% homologous (identical, respectively 
complementary) to the respective marker target sequence. 
Suitable examples for sequence specific oligonucleotides are 
also indicated in Table 5. The respective miRNAs are specifi-
45 cally/differentially expressed in saliva samples and are thus 
suitable markers for determining/identifying an unknown 
sample as a saliva sample. It is advantageous that at least two 
small non-coding RNAs are selected from the following 
group of small non-coding RNAs as markers for saliva: 
50 
or an isoform thereof (having no more than 5, preferably no 
more than 3 or more preferred no more than 2 base changes) 55 
and/or a small non-coding RNA derived from the same 
premiRNA. It was demonstrated in extensive experiments by 
the inventors that the respective miRNAs are particularly 
specific markers for semen which thus allow the secure iden-
tification/determination of an unknown sample as a semen 60 
sample. 
The kit may comprise additionally or alternatively at least 
one oligonucleotide specific for at least one small non-coding 
RNA selected from the group of small non-coding RNAs 
listed in Table 4 (see FIG. 4) or an isoform thereof (having no 65 
more than 5, preferably no more than 3 or more preferred no 

















or an isoform thereof (having no more than 5, preferably no 
more than 3 or more preferred no more than 2 base changes) 
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and/or a small non-coding RNA derived from the same 
premiRNA. It was demonstrated in extensive experiments by 
the inventors that the respective miRNAs are particularly 
specific markers for saliva which thus allow the secure iden-
tification/determination of an unknown sample as a saliva 
sample. 
Preferably, the kit comprises oligonucleotides for at least 
two different marker small non-coding RNAs per particular 
sample type. 
Furthermore, the kit may comprise at least one sequence 10 
specific oligonucleotide for detecting a small non-coding 
RNA for normalization. Preferably, the small non-coding 
RNA detected for normalization has a Ct value close to the Ct 
value of the marker small non-coding RNA. The kit may 15 
comprise at least one sequence specific oligonucleotide for 
detecting a small non-coding RNA selected from the group 
consisting ofU 6B, U 44, S 15 or miRNAs which have a similar 
Ct value in all sample types of interest. Details are outlined 
above, we refer to our above disclosure. 20 
The kit may additionally comprise at least one of the fol-
lowing components 
a. buffers and/or reagents for isolating RNA from a sample 
b. buffers and/or reagents for reverse transcribing RNA 
c. buffers and/or reagents for amplification and/or detec- 25 
ti on. 
Details regarding the isolation, amplification and detection 
were outlined above; we refer to the respective disclosure. 
The kit may also comprise a universal oligonucleotide that 
can be used in combination with the sequence specific oligo- 30 
nucleotide for amplifying the small non-coding RNAs. 
A respective kit is particularly useful in for identifying the 
nature and in particular the origin and type of forensic 
samples as it provides a reliable tool for determining the 
nature of even small samples, in particular forensic samples. 35 
Also provided is an oligonucleotide set for determining the 
nature of a sample, said set comprising oligonucleotides for 
detecting at least two different small non-coding RNAs per 
sample type, wherein said oligonucleotide set has at least one 
of the following characteristics: 40 
a. It comprises oligonucleotides hybridising to at least two 
small non-coding RNAs comprising or consisting of a 
























or hybridising to an isoform thereof (having no more 
than 5, preferably no more than 3 or more preferred no 
more than 2 base changes) and/or miRNA derived from 65 
the same premiRNA as the respective miRNAs, prefer-
ably miR451 and miR16, as markers for blood; 
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b. and/or it comprises oligonucleotides hybridising to at 
least two small non-coding RNAs comprising or con-





















or hybridising to an isoform thereof (having no more 
than 5, preferably no more than 3 or more preferred no 
more than 2 base changes) and/or miRNA derived from 
the same premiRNA as the respective miRNAs, prefer-
ably miR412 and miR451, as markers for menstrual 
blood; 
c. and/or it comprises oligonucleotides hybridising to at 
least two small non-coding RNAs comprising or con-


















or hybridising to an isoform thereof (having no more 
than 5, preferably no more than 3 or more preferred no 
more than 2 base changes) and/or miRNA derived from 
the same premiRNA as the respective miRNAs, prefer-
ably miRl 35b and miRl Ob, as markers for semen; 
d. and/or at it comprises oligonucleotides hybridising to at 
least two small non-coding RNAs comprising or con-






or hybridising to an isoform thereof (having no more 
than 5, preferably no more than 3 or more preferred no 
more than 2 base changes) and/or miRNA derived from 
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the same premiRNA as the respective miRNAs, prefer-
ably miR124a, miR372 and miR195, as markers for 
vaginal secretions; 
e. and/or it comprises oligonucleotides hybridising to at 
least two small non-coding RNAs comprising or con- 5 
sisting of a sequence selected from the group of 
10 
20 
FIG. 6 shows, as an example, the results of a miRNA 
candidate screening using pooled body fluid samples. The 
graph shows absolute Ct values for 25 miRNAs for the pooled 
body fluid samples for identification of possible miRNA 
marker candidates for the individual body fluids, namely 
blood, semen, saliva, vaginal secretions and menstrual blood. 
Each body fluid is represented by a symbol (blood--dia-
mond; semen-small square; saliva-triangle; vaginal secre-
tions-large square; menstrual blood-circle). 
As can be seen, only few miRNAs depict an expression 
profile which makes them suitable as marker small non-cod-
ing RNAs according to the present invention. For example, 
the graph shows that the miRNAs miR15a, miR15b and 


















15 a desirable discrimination profile compared to the other body 
fluids analysed. They can thus be used as a marker for blood. 
FIG. 7A to E shows the development of2-D miRNA body 
fluid identification assays. Different samples from different 
donors were used. Body fluid data clustering using 2-D scat-
or hybridising to an isoform thereof (having no more 
than 5, preferably no more than 3 or more preferred no 
more than 2 base changes) and/or miRNA derived from 
the same premiRNA as the respective miRNAs, prefer-
ably miR658 and miR205, as markers for saliva. 
20 ter plots constructed with U6b normalised expression data for 
two miRNAs that were particularly advantageous markers for 
the respective fluid is shown. The blood assay (FIG. 7A) 
shows in the X-axis the llCt miR16 (U6b-miR16), the Y-axis 
the fl Ct miR451 (U6b-miR451 ). The semen assay (FIG. 7B) 
A respective oligonucleotide set is particularly useful for 
identifying/typing samples, in particular body fluids. The 
features of the respective small non-coding RNAs are 
described in detail above. Each oligonucleotide hybridises to 
25 shows on the X-axis thellCtofmiR135b (U6b-miR135b ), the 
Y-axis shows the llCt ofmiRlOb (U6b-miR10b). The saliva 
assay (FIG. 7C) shows on the X-axis the llCt of miR205 
(U6b-miR205) and on the Y-axis the fl-Ct ofmiR658 (U6b-
miR658). The vaginal secretion assay (FIG. 7D) shows on the 
30 X-axis the fl Ct of miRl 24a (U6b-miR124a) and on the Y-axis 
the llCT of miR372 (U6b-miR372). The menstrual blood 
assay (FIG. 7E) shows on the X-axis llCt miR451 (U6b-
miR451), the Y-axis shows the llCt miR412 (U6b-miR412). 
its specific/corresponding marker small non coding RNA. 
Hence, ifthe set comprises oligonucleotides hybridising to at 
least two small non-coding RNAs, at least two different oli-
gonucleotides are provided wherein each oligonucleotide 
recognises a specific marker small non coding RNA. The 
oligonucleotides do not need to recognise both sequences 
even though this option is included. Some small non coding 40 
RNAs exist with minor sequence variations (e.g. miRNA 
isoforms having less than 5, preferably 2 or 3 base changes or 
less). They are also encompassed as the individual oligo-
nucleotides can be designed that they also recognize and 
hybridise to respective miRNA isoforms or miRNAs which 45 
are derived from the same premiRNA. 
The body fluids are presented by symbols. The blood is 
35 represented by squares, the semen by diamonds, saliva by 
triangles, vaginal secretions by a circle and menstrual blood 
by open squares. The body fluid of interest on each assay is 
circled and labelled. 
FIG. 1-5 show tables 1-5 which depict suitable miRNAs 
which are useful markers for different samples, namely blood 
(FIG. 1/Table 1), menstrual blood (FIG. 2/Table 2), semen 
(FIG. 3/Table 3), vaginal secretions (FIG. 4/Table 4) and 50 
saliva (FIG. 5/Table 5). 
As is also shown in FIG. 9, a mature miRNA is made from 
a stem loop precursor, typically from one leg of the stem. 
When the other leg is detected as a minor component in the 
cells, it gets the asterisk. When both strands are detected as 55 
relatively equal contributors, they get 3p and 5p suffix (de-
pending on whether they are closer to the 5' or 3' end of the 
premiRNA). Some miRNA have an identical mature 
sequence but different names. This naming schema corre-
sponds to the one of miRBase. If several isoforms of a miRNA 60 
exist that can be detected, respective isoforms (having suf-
fices a, b, c etc). Isoforms differ in only a few bases, usually 
less than 3. Further isoforms may exist, which are not listed 
but could also be detected according to the teachings of the 
present invention. "hsa" is the designation for human miRNA 65 
sequence. Particularly preferred variants/isoforms are indi-
cated in the tables. 
A pair of markers was used, as the use of two markers 
provides more security for identifying/typing a specific 
sample. As can be seen, the tested markers are plotted in the 
shown 2-D assay in the same quadrant which indicates that 
they are equally suitable. Furthermore, as can be seen from 
the results obtained from the different samples, the tested 
markers are also highly specific for their respective sample 
type. 
FIG. 8 demonstrates the stability of miRNA expression 
even in environmentally compromised blood samples. 
FIG. 9 illustrates the generation of mature miRNAs 
according to one assumed embodiment (figure obtained from 
public sources). The genes encoding miRNAs are much 
longer than the processed mature miRNA molecule. miRNAs 
are first transcribed as primary transcripts or pri-miRNA with 
a cap and poly-A tail and processed to short, approximately 
70-nucleotide stem-loop structures known as pre-miRNA in 
the cell nucleus. This processing is performed in animals by a 
protein complex known as the Microprocessor complex, con-
sisting of the nuclease Drosha and the double-stranded RNA 
binding protein Pasha. These pre-miRNAs are then processed 
to mature miRNAs in the cytoplasm by interaction with the 
endonuclease Dicer, which also initiates the formation of the 
RNA-induced silencing complex (RISC). This complex is 
responsible for the gene silencing observed due to miRNA 
expression and RNA interference. The pathway is also differ-
ent for miRNAs derived from intronic stem-loops; these are 
processed by Dicer but not by Drosha. Either the sense strand 
or antisense strand of DNA can function as templates to give 
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rise to miRNA. Most pre-miRNAs don't have a perfect 
double-stranded RNA (dsRNA) structure topped by a termi-
nal loop. There are few possible explanations for such selec-
tivity. One could be that dsRNAs longer than 21 base pairs 
activate interferon response and anti-viral machinery in the 
cell. Another plausible explanation could be that the thermo-
dynamic profile of pre-miRNA determines which strand will 
22 
months sample is represented by an open diamond. As can be 
seen, the results are basically identical for all samples despite 
the fact that the additionally tested blood samples were aged/ 
heat treated. The results demonstrate, that for example, blood 
stains kept at room temperature for even two years and even at 
elevated temperatures still cluster as blood stains and can thus 
be securely identified by detecting the marker miRNAs. This 
proves that the present detection method is highly reliable 
also for difficult and/or compromised samples, which are 
10 often encountered in forensic samples. The marker miRNA 
are stable in the sample and thus provide a reliable markerthat 
can be detected to identify/type samples. Additional test were 
performed. 
be incorporated into Dicer complex. Indeed, clear similarities 
between pri-miRNAs encoded in respective ( 5'- or 3 '-) strands 
have been demonstrated. When Dicer cleaves the pre-miRNA 
stem-loop, two complementary short RNA molecules are 
formed, but only one is integrated into the RISC complex. 
This strand is known as the guide strand and is selected by the 
argonaute protein, the catalytically active RNase in the RISC 
complex, on the basis of the stability of the 5' end. The 15 
remaining strand, known as the anti-guide or passenger 
strand, is degraded as a RISC complex substrate. After inte-
gration into the active RISC complex, miRNAs base pair with 
their complementary mRNA molecules and induce mRNA 
degradation by argonaute proteins, the catalytically active 
members of the RISC complex. 
Example 3 
Additional Experiments 
To further substantiate the respective results, additional 
20 experiments were performed. 
3.1. Methods 
a.) Preparation of Body Fluid Stains 
EXAMPLES 
For identifying useful marker small non-coding RNAs and 
in particular miRNAs, the commercially available "Human 
miScript Oligonucleotide Assay Set Vl .0-miRNA-specific 
oligonucleotides for 452 human miRNAs"; QIAGEN cat no 
218411 can be used to screen for markers useful in forensic 
testing. Suitable candidates are listed in FIG. 1 to 5. 
Example 1 
Tissue Identification 
Body fluids were collected from volunteers using proce-
dures approved by the University of Central Florida's Insti-
25 tutional Review Board. Informed written consent was 
obtained from each donor. Blood samples were collected by 
venipuncture into additive-free vacutainers and 50 µl aliquots 
were placed onto cotton cloth and dried at room temperature. 
Freshly ejaculated semen was provided in sealed plastic tubes 
30 and stored frozen until they were dried onto sterile cotton 
swabs. Saliva samples were provided in sealed plastic tubes 
and stored frozen until they were dried onto sterile cotton 
swabs. Buccal samples were collected from donors using 
sterile swabs by swabbing the inside of the donor's mouth. 
35 Semen-free vaginal secretions and menstrual blood were col-
lected using sterile cotton swabs. All samples were stored at 
-20° C. until needed. A 50 µl stain or a single cotton swab was 
used for RNA isolation. 
4 different sample types are collected from 5 different 
individuals of different sex (if applicable) and age: semen, 
blood, saliva, vaginal secretion. RNA is extracted from these 
samples and RNA pools are generated from RNA from all 5 
donors. RNA is quantified and subjected to real time PCR 40 
based analysis to determine expression levels for the indi-
vidual miRNAs respectively. Candidate miRNAs are identi-
fied that show significantly heightened or lowered expression 
levels for certain samples, e.g. body fluids. 
Total RNA from 20 human tissues (adipose, bladder, brain, 
cervix, colon, esophagus, heart, kidney, liver, lung, ovary, 
placenta, prostate, skeletal muscle, small intestine, spleen, 
testes, thymus, thyroid, and trachea) included in the 
FirstChoice® Human Total RNA Survey Panel was obtained 
from Applied Biosystems/Ambion (Austin, Tex.). All tissues 
Example 2 
Stability 
Different sample types (semen, blood, saliva, vaginal 
secretion) are collected, stored at room temperature and total 
RNA is extracted at different time points from 0 to 18 months. 
miRNAs are found to be highly stable. 
The ability to detect the body fluids in environmentally 
compromised biological stains was evaluated by the analysis 
of samples stored at room temperature (one year and two 
years) and at 37° for six months. The blood assay was per-
formed as described above. The markers miRl 6 and MiR451 
were used for detection. The X-axis indicates the ti.Ct of 
miR16, the Y-axis the ti.Ct ofmiR451. 
Several body fluids and the compromised samples were 
tested. Blood is indicated by squares, semen by diamonds, 
saliva by triangles and vaginal secretions by circles. The 
known blood samples (see above) are circled in the graph. The 
room temperature one year sample is represented by an open 
triangle in the blood section, the room temperature two year 
sample is represented by an open square and the 37° six 
45 included in the panel were 3-donor pooled samples and were 
certified to contain small RNAs including miRNAs and snR-
NAs. Total RNA from human skin was obtained from Bio-
chain Institute, Inc (Hayward, Calif.). 
Blood samples from 12 non-primate animal species (dog, 
50 cat, horse, crane, cow, sheep, coyote, tortoise, lamb, Patago-
nian cavy, ferret, deer) and 10 primate species (spider mon-
key, rhesus macaque, pig-tailed macaque, brown lemur, 
chimpanzee, baboon, howler monkey, cynomolgous monkey, 
African green monkey, and spot-nosed guenon) were 
55 obtained from various sources: Tuscawilla Oaks Animal Hos-
pital, Oviedo, Fla. (dog, cat); HemoStat Laboratories, Dixen, 
Calif. (sheep, cow, horse); Central Florida Zoo, Sanford, Fla. 
(brown lemur, howler monkey, spot-nosed guenon); Brevard 
Zoo, Melbourne, Fla. (crane, coyote, tortoise, lamb, Patago-
60 nian cavy, spider monkey, rhesus macaque, pig-tailed 
macaque); donation from laboratory members (coyote, deer); 
West End Animal Hospital, Gainesville, Fla. (ferret). Liquid 
blood samples from African green monkey, cynomolgus 
monkey, baboon and chimpanzee were obtained from Biorec-
65 lamation, Inc. (Westbury, N.Y.). For all blood samples, fifty 
microliter aliquots were placed on cotton cloth and dried 
overnight at room temperature. 
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Saliva samples from two cats and two dogs were collected 
by swabbing the inside of the animal's mouth using sterile 
cotton swabs. A primate saliva sample (spot-nosed guenon) 
was obtained by donation from the Central Florida Zoo (San-
ford, Fla.). 
b) RNA Isolation 
Total RNA was extracted from blood, semen, saliva, vagi-
nal secretions and menstrual blood with guanidine isothiocy-
anate-phenol:chloroform and precipitated with isopropanol 
[58]. Briefly, 500 DI of pre-heated (56° C. for 10 minutes) 
denaturing solution ( 4M guanidine isothiocyanate, 0.02M 
sodium citrate, 0.5% sarkosyl, O.lM beta-mercaptoethanol) 
was added to a 1.5 mL Safe Lock tube extraction tube (Eppen-
dorf, Westbury, N.Y.) containing the stain or swab. The 
samples were incubated at 56° C. for 30 minutes. The swab or 
stain pieces were then placed into a DNA IQ™ spin basket 
(Promega, Madison, Wis.), re-inserted back into the original 
extraction tube, and centrifuged at 14,000 rpm (16,000xg) for 
5 minutes. After centrifugation, the basket with swab/stain 
pieces was discarded. To each extract the following was 
added: 50 µI 2 M sodium acetate and 600 µI acid phenol: 
chloroform (5: 1 ), pH 4.5 (Applied Biosystems/Ambion). The 
samples were placed at 4 ° C. for 30 minutes to separate the 
layers and then centrifuged for 20 minutes at 14,000 rpm 
(16,000xg). The RNA-containing top aqueous layer was 
transferred to a new 1.5 ml microcentrifuge tube, to which 2 
24 
RT-reaction (blood, saliva, vaginal secretions, menstrual 
blood) and two microliters of the 5 ng RT-reaction (semen) 
were amplified using the miScript SYBR® Green PCR kit 
and a 1 Ox miScript primer assay (Human mi Script Primer 
5 Assay Set vl.O, Qiagen) according to manufacturer's proto-
cols, with minor modifications. A reduced reaction volume of 
25 µI was used as well as an increased number of amplifica-
tion cycles (from 35-40 to 50 cycles). Additional snRNA 
(U6b)andsnoRNA(U26, U27, U28, U29, U30, U31, U38B, 
10 U43, U44, U48 and U90) primer assays for normalization 
studies were obtained from Qiagen. 
g) Menstruation Cycle Samples 
Two female individuals donated vaginal swabs over the 
15 
course of a 28-day period. Females at two different life stages 
participated in the study, one experiencing menstruation at 
regular intervals and one in perimenopause. Participants were 
asked to collect a single semen-free vaginal swab during each 
day of the study, with the first day of collection starting on the 
20 first day of menstruation if applicable. 
h) Multiple-Source Samples 
Pooled Samples 
Five-donor pooled samples were used for the initial 
miRNA screening in forensically relevant fluids. Total RNA 
25 from each individual sample was extracted and quantitated as 
described above. Equal quantities of total RNA from each 
donor were combined in order to produce a 1 ng/01 pooled 
sample for blood, saliva, vaginal secretions and menstrual 
blood, and a 5 ng/µl pooled sample for semen. A 1 µI aliquot 
µI of GlycoB!ue™ glycogen carrier (Applied Biosystems/ 
Ambion) and 500 µI of isopropanol were added. RNA was 
precipitated for 1 hour at -20° C. The extracts were then 
centrifuged at 14,000 rpm (16,000xg). The supernatant was 
removed and the pellet was washed with 900 µI of 75% 
ethanol/25% DEPC-treated water. Following a centrifugation 
for 10 minutes at 14,000 rpm (16,000xg), the supernatant was 
removed and the pellet dried using vacuum centrifugation 
(56° C.) for 3 minutes. Twenty microliters of pre-heated (60° 35 
C. for 5 minutes) RNAsecure™ solution (Applied Biosys-
tems/Ambion) was added to each sample followed by an 
incubation at 60° C. for 10 minutes. Samples were used 
immediately or stored at -20° C. until needed. 
30 of each pooled sample was used in the reverse transcription 
assay. 
Two Fluid Mixtures 
Admixed body fluid samples (blood-semen, blood-saliva, 
blood-vaginal secretions, semen-saliva, semen-vaginal secre-
tions and saliva-vaginal secretions) were created by combin-
ing two different body fluid stains or swabs (50 µI stain for 
blood, semen and saliva, or a single vaginal secretion swab) in 
the same tube. Total RNA was extracted as described above. 
i) Mock Casework Samples 
c) DNase I Digestion 40 Saliva Samples 
Six units of TURBO™ DNase I (2U/µl) (Applied Biosys-
tems/Ambion, Inc.) and2.2 µI ofTurbo DNase I Buffer(lOx) 
were added to each RNA extract and incubated at 37° C. for 
Swabs of a beverage container lid (plastic coffee cup lid, 
water bottle) using a sterile cotton swab were collected after 
being deposited by volunteers. Saliva from a male donor was 
deposited onto the skin of a female donor. Afterthe saliva was 1 hour. The DNase was inactivated at 75° C. for 10 minutes. 
The samples were used immediately or stored at -20° C. until 
needed. Alternatively, DNase digestion was performed using 
the Turbo DNA-free™ kit (Applied Biosystems/Ambion) 
according to the manufacturer's protocol. 
d) RNA Quantitation 
45 allowed to dry, the skin was swabbed using a sterile cotton 
swab. Portions of the outer wrapping of used cigarette butts 
(collected from a male and female donor) were removed for 
extraction. Total RNA was extracted as described above. 
3.2. Results 
RNA extracts were quantitated with Quant-iT™ 
RiboGreen® RNA Kit (Invitrogen, Carlsbad, Calif.). Fluo-
rescence was determined using a Synergy™ 2 Multi-Mode 
microplate reader (BioTek Instruments, Inc., Winooski, Vt.). 
50 3.2.1. miRNA BodyF!uID Specificity 
a) Body Fluid/Tissue Specificity 
e) cDNA Synthesis 
The initial studies were performed using five samples per 
body fluid ( se above). In order to ensure the specificity of each 
assay, additional body fluid samples were tested (n= 10-20 for 
55 the body fluid of interest, n=8- l 0 for the other body fluids not 
being assayed for). 
For the reverse transcriptase (RT) reaction, the miScript 
Reverse Transcription Kit (Qiagen, Valencia, Calif.) was used 
according to manufacturer's protocols. One nanogram of 
total RNA from blood, semen, vaginal secretions and men-
strual blood extracts and 5 ng of total RNA from semen 
extracts were used in the RT reactions. A reverse transcription 60 
negative reaction (containing total RNA and reaction buffer 
but no reverse transcriptase enzyme mix) was performed for 
each sample. 
f) Real-Time Polymerase Chain Reaction 
Real-time PCR was performed using the Relative Quanti- 65 
tation protocol on an ABI Prism 7000 Sequence Detection 
System (Applied Biosystems). One microliter of the 1 ng 
Blood 
Nineteen human blood samples (including the five previ-
ously tested samples) were analyzed using the blood miRNA 
assay (miR16/deltaCt miR451). The blood sample donors, 
both male and female, ranged in age from 15 months to 84 
years old. As before, all of the human blood samples were 
found in a distinct cluster in the upper right quadrant sepa-
rated from all other body fluids. All vaginal secretion samples 
were found in the lower left quadrant and there was consid-
erable overlap of the semen and saliva samples, which were 
spread out over the two lower quadrants and the upper right 
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quadrant. The buccal samples were located closer to the blood 
samples than any of the other fluids but were still well sepa-
rated from each other. 
Semen 
Eleven human semen samples (five previously tested 
samples included) were tested using the semen miRNA assay 
(deltaCt miR135b and deltaCt miRlOb). Samples were 
obtained from adult males ranging in age from 26-52 years 
old. All of the semen samples are found in a distinct cluster 
separated from all other body fluids. Samples from two vasec-
tomized males were included in the study in order to deter-
mine ifthe semen assay was specific to sperm cells. Both of 
the samples from the vasectomized males were detected 
amongst the semen samples from non-vasectomized males, 
thereby demonstrating the ability of the assay to accommo-
date non-sperm containing semen samples. The detection of 
semen from both vasectomized and non-vasectomized males 
could indicate that the two semen miRNA candidates are 
present in seminal fluid or in epithelial cells from the male 
reproductive tract. Overall, fewer miRNAs were detected in 
semen compared to the other biological fluids and those that 
were present were often found in much lower abundance. The 
low abundance of these miRNAs may be explained if detec-
tion is obtained from the low level of non-sperm cells present 
in semen. The cellular and non-cellular components of semen 
could be separated and examined for the presence of both of 
the semen miRNA candidates to determine if the miRNAs 
used in the semen assay are cellular based. 
Saliva 
Eighteen human saliva samples (including the five previ-
ously tested samples) were tested using the saliva miRNA 
assay (miR205/miR658). Samples were obtained from both 
male and female donors ranging in age from 26-58 years old, 
and included both liquid whole saliva samples (n=9) and 
buccal swabs (n=9). All of the liquid saliva and buccal scrap-
ings samples were located together in a distinct cluster sepa-
rate from the other body fluids tested. They were clustered in 
the upper right quadrant with the exception of one buccal 
sample which, although part of the cluster, was slightly out-
side the quadrant. The vaginal secretions, blood and semen 
samples were mainly located in the lower left quadrant with a 
few samples just inside the lower right quadrant. The ability 
to identify both liquid saliva and buccal samples is an impor-
tant finding since both whole saliva and buccal cells are 
encountered in forensic specimens. 
Vaginal Secretions 
Eleven vaginal secretion samples (including the five pre-
viously analyzed samples) were collected from adult females 
ranging in age from 28-65 years old and tested using the 
vaginal secretions miRNA assay (miR124a/deltaCt miR372). 
All vaginal secretion samples, except for one 'false negative', 
were located together in a distinct cluster in the lower right 
quadrant separate from the other body fluids. Since the whole 
saliva sample set was the closest to the vaginal cluster, addi-
tional saliva samples comprising five buccal epithelial 
samples were tested using the vaginal secretions assay in 
order to determine whether the vaginal epithelial and oral 
epithelial cells were distinguishable. While the buccal epithe-
lial cells clustered closer to the vaginal secretion data points 
than the whole saliva samples, there was still a clear separa-
tion between the two body fluids. 
Other Human Tissues 
Despite reports in the current literature of the identification 
of tissue-specific miRNAs, it has been suggested that a major-
ity of miRNAs will be expressed in the majority of tissues. 
While all of the miRNAs included in the body fluid identifi-
cation panel described above were detected in each body 
26 
fluid, their differential expression enabled each of the four 
body fluids to be distinguished. 
Total RNA from twenty-one human tissues including adi-
pose, brain, cervix, heart, liver, lung, placenta, prostate, skel-
etal muscle, testes, thyroid, trachea, bladder, spleen, thymus, 
ovary, kidney, colon, esophagus, small intestine 
(FirstChoice® Human Total RNA Survey Panel, Applied 
Biosystems/Ambion) and skin (Biochain Institute, Inc.), was 
analyzed using the miRNA panel. Each total RNA sample 
10 included in the FirstChoice® panel comprised RNA from at 
least three different donors and was certified to contain small 
RNAs (miRNA, siRNA and snRNA). As expected, the miR-
NAs included in the panel were detected in each of the tissue 
samples but again in varying abundance. The high degree of 
15 specificity of each of the miRNA body fluid identification 
assays was confirmed since all of the tissue samples exhibited 
expression profiles that differed from that of the appropriate 
body fluid in each of the four assays discussed above. 
For the blood assay, both miR16 and miR451 were 
20 detected in all twenty-one tissues with the exception of the 
small intestine where miR451 was not detected. MiR451 was 
found in the highest abundance in lung and placenta whereas 
miRl 6 was found in the highest abundance in lung and pros-
tate. However, despite their higher abundance in these tissues 
25 compared to the rest of the samples, their abundance was still 
lower than that in human blood samples. When the tissue 
samples were evaluated using blood assay and the data ana-
lyzed using the 2D scatter plot, all of the tissue samples were 
present in the lower left quadrant of the scatter plot whereas 
30 the blood samples were tightly clustered in the upper right 
quadrant. 
Both the semen markers, miRl 35b and miRl Ob, were also 
detected in all of the twenty-one tissues with many present in 
moderate to high abundance. MiR135b was detected in high-
35 est abundance in testes and thyroid, whereas miRl Ob was 
detected in high abundance in numerous tissues including 
testes, adipose, cervix, ovary, kidney and colon. As a result of 
the high abundance of these miRNAs in numerous tissues, the 
separation between the human semen sample cluster and the 
40 tissue samples was not as great in the 2D scatter plot as that 
observed for the blood assay. 
One of the saliva miRNA markers, miR658, was present in 
low abundance in all of the tissue samples. MiR205 was 
present in moderate abundance in the cervix, placenta and 
45 prostate tissue but in low abundance in all other tissues. The 
2D plot showed the tissue samples located in the lower left 
quadrant with a significant separation from the saliva 
samples, which were located in the upper right quadrant. 
For the vaginal secretions assay all tissue samples were 
50 located in the lower left quadrant separated from the vaginal 
secretions samples that were located in the lower right quad-
rant. Several published studies have identified miR124a as a 
brain-specific miRNA. While miR124a was found in highest 
abundance in brain compared to the other tissues examined, 
55 the expression level observed in brain was still lower than that 
we observed for vaginal secretions. Due to these differences 
in expression, the brain sample was located closer to the 
vaginal secretions samples on the two-dimensional plot but 
was still present in the lower left quadrant. The Ct values for 
60 miR372 rangedfrom32 to >40 for all tissue samples, with the 
lowest Ct value obtained from placenta. 
Species Specificity 
Optimal forensic analysis not only requires an assay to 
possess tissue specificity but it also should exhibit restricted 
65 species specificity. To check this, a number of non-human 
blood samples were analyzed including twelve animal spe-
cies (dog, cat, horse, crane, cow, coyote, sheep, tortoise, lamb, 
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Patagonian cavy, ferret, deer) and ten non-human primate 
species (spider monkey, rhesus macaque, pig-tailed macaque, 
brown lemur, chimpanzee, baboon, howler monkey, cyno-
molgus monkey, African green monkey, spot-nosed guenon). 
28 
U44-normalized assay could be used to identify the presence 
of human or higher primate blood if a positive result for an 
unknown sample was obtained using the U6b-normalized 
blood assay. 
b) Simulated Forensic Casework Samples 
The initial studies described above demonstrated the sen-
sitivity (50 pg ofinput cDNA), specificity (no cross-reactivity 
with human tissues) and stability (detection in environmen-
tally compromised samples) of the developed miRNA assays 
A smaller number of non-human saliva samples were avail-
able tested and included cat, dog and one primate (spot-nosed 
guenon). Semen and vaginal secretion samples from non-
human species were not available for testing, but such body 
fluids from non-human species are rarely encountered in 
casework. 
For all of the non-human species blood samples, miR451, 
miR16, and U6b were detected in significant abundance. All 
10 for body fluid identification. However, forensic evidentiary 
items may contain only trace amounts of genetic material and 
may also include the presence of multiple different biological 
fluids. Thus it is important to test the performance of the 
miRNA BodyFluID assays according to the present invention 
of the non-human samples were found in close proximity to 
the human blood data points. Two animals (ferret and coyote) 
and four primates (chimpanzee, baboon, African green mon-
key, and cynomolgus monkey) were located directly within 
the human blood cluster. While only a small number of the 
species tested were clustered within the human blood 
samples, the small distance between the human data points 
and the remaining animal species would make it difficult to 20 
differentiate human and non-human blood samples with any 
degree of confidence using this assay. 
15 with such samples and we accomplished this by the prepara-
tion and analysis of simulated casework samples. 
Saliva samples from two dogs and two cats were used to 
examine the species specificity of the saliva miRNA assay. 
Negative results (i.e. not found in the human saliva data 25 
cluster) were obtained for the both of the cat and dog samples. 
While an extensive number of animal saliva samples were not 
available for testing, cat and dog represent animals that could 
Saliva 
Genetic profiles can be routinely recovered from trace 
amounts of salivary fluids from items such as used cigarette 
butts and beverage containers. Therefore if the presence of 
trace amounts of saliva could be detected on these items, it 
may provide investigators with an indication of which evi-
dentiary items may be useful for the subsequent recovery of 
DNA. Furthermore, saliva recovered from the skin of a victim 
could be useful in the investigation of oral assault cases. In 
order to determine if the saliva miRNA assay could detect 
trace amounts of saliva in such samples, total RNA was recov-
ered from swabs of beverage container lids, human skin on 
which saliva had been deposited, and used cigarette butts. All be frequently encountered at crime scenes in forensic case-
work. 30 of the simulated casework samples, except for one of the 
swabs taken from a beverage container lid, were located clus-
tered with the known human saliva samples in the upper right 
quadrant. 
As a result of the observed species specificity of the blood 
assay, an improvement was developed in order to provide a 
more forensically relevant assay. Attempts were made to 
identify an alternative small RNA to be used for normaliza-
tion of the miRNA expression data that would also allow for 35 
a differentiation of human and non-human blood stains. The 
expression of 11 small nucleolar RNAs (snoRNAs), includ-
ing U26, U27, U28, U29, U30, U31, U38B, U43, U44, U48 
and U90, was examined in both human and non-human blood 
samples in order to determine if a human specific normalizer 40 
could be identified. Several of the snoRNAs, including U26, 
U28, U30, U44, and U90, were found in very low abundance 
or were not detected in the non-human samples. However, the 
abundance of these snoRNAs in the some of the human body 
fluids was also quite low. For example, the Ct value for U44, 45 
U26, U28, and U90 in semen was over 40 whereas the Ct for 
U30 was acceptable for semen but was close to 40 for blood 
and saliva. Therefore, none of the snoRNAs tested were deter-
mined to be suitable for use a universal normalizer for all 
body fluids. 50 
While an alternative universal normalizer was not identi-
fied, several of the snoRNAs, including U26, U28 and U44, 
were present in low abundance in non-human blood samples 
and in higher abundance in human blood samples. Therefore, 
it was possible that one of these snoRNAs could be used to 55 
normalize only the blood assay and provide the desired spe-
cies specificity. U44 was selected as the top snoRNA candi-
date due to its high abundance in blood, its low abundance in 
the animal blood samples, but also because of its low abun-
dance or absence in most of the primate samples. When the 60 
2D scatter plot was constructed using the U44-normalized 
data, the clustering that was achieved with the U6b-normal-
ized assay was not achieved and overlap of the semen, saliva 
and blood data was observed. However, it was evident from 
the 2D scatter plot that there was a clear separation between 65 
the human blood data points and the non-human blood 
samples. Based on these results, it was determined that the 
Blood 
Total RNA was recovered from the cotton pad of an adhe-
sive bandage used to cover a small cut on the finger of a 
female donor. The cotton pad of the bandage contained blood 
in the form of a small reddish-brown stain. When the bandage 
sample was evaluated with the blood assay, the sample data 
was located in the upper right quadrant on the two-dimen-
sional scatter plot clustered with the known blood samples. 
The same sample was subsequently evaluated with the U44-
normalized blood miRNA assay in order to determine ifthe 
blood present on the bandage was of human origin. The 
location of the sample on the two-dimensional U44-normal-
ized scatter plot was upper right quadrant clustered with the 
known human blood samples confirming the presence of 
human blood present on the bandage. 
Semen and Vaginal Secretions 
A significant number of samples processed in an opera-
tional forensic DNA laboratory involve the analysis of evi-
dence recovered from sexual assaults. Often only a small 
amount of semen from the perpetrator will be present 
amongst a vast excess of a female victim's biological mate-
rial. For an assay to be useful in forensic casework, it must be 
able to detect the small amount of semen that may be present 
and not be masked by the excess vaginal material present. In 
order to determine the potential utility of the semen miRNA 
assay forthe analysis of sexual assault evidence, a vaginal and 
cervicovaginal swab was collected from a female donor 18 
hours post-coitus. The vaginal and cervicovaginal swabs 
were collected in order to determine if semen would be 
detected in different regions of the vaginal canal. To insure 
that residual semen from prior sexual relations were not 
present, a pre-coital cervicovaginal swab was also obtained 
before coitus commenced but after an abstinence period of 
seven days. The presence of semen was detected on both the 
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vaginal and cervicovaginal swabs taken 18 hours post-coitus. 
The pre-coital swab was negative for the presence of semen. 
The presence of vaginal secretions was detected in the vaginal 
swab, cervicovaginal swab and the pre-swab using the vagi-
nal secretions assay. 
Body Fluid Mixtures 
30 
clustered with the known samples on each plot. The absence 
of blood and vaginal secretions was also demonstrated. 
The examples demonstrate that miRNAs are present in 
total RNA isolates from body fluid stains in sufficient quantity 
for analysis. A preferred panel of 9 differentially expressed 
miRNAs for the identification of the body fluid origin of 
biological stains was tested using suitable oligonucleotides in 
detail as described above. The following marker miRNAs are 
included in said panel: miR451 and miRl 6 for the identifica-
10 tion of blood, miR135b and miRlOb for the identification of 
semen, miR658 and miR205 for the identification of saliva, 
miRl 24a and miR3 72 for the identification of vaginal secre-
tions, and miR412 which is used in combination with the 
Body fluid mixtures other than the common semen-vaginal 
secretions encountered in sexual assault cases may also be 
present in forensic evidentiary samples. Thus additional body 
fluid mixtures samples, including two blood-semen and one 
semen-saliva mixtures were also evaluated. The miRNA 
expression profile for each mixture using all four body fluid 
assays (blood, semen, saliva, and vaginal secretions) was 
determined. Blood and semen were correctly identified in 15 
both of the blood-semen mixture samples. On the blood assay, 
the admixed samples were located in the upper right quadrant 
clustered with the known blood samples. On the semen assay, 
the samples were located in the upper portion of the lower 
right quadrant clustered with the known semen samples. The 20 
absence of saliva and vaginal secretions was also demon-
strated with the blood-semen mixture samples located in the 
lower left quadrants. Semen and saliva were also correctly 
identified in the semen-saliva mixture sample with the sample 
<160> NUMBER OF SEQ ID NOS, 
<210> SEQ ID NO 1 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo 
<400> SEQUENCE, 1 
ugagguagua gguuguauag 
<210> SEQ ID NO 2 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo 
<400> SEQUENCE, 2 
ugagguagua gguugugugg 
<210> SEQ ID NO 3 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo 
<400> SEQUENCE, 3 
ugagguagua gguuguaugg 
<210> SEQ ID NO 4 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo 
<400> SEQUENCE, 4 
agagguagua gguugcauag 
<210> SEQ ID NO 5 
<211> LENGTH, 22 









<213> ORGANISM, Homo sapiens 
SEQUENCE LISTING 
227 
blood candidate miR451 for the identification of menstrual 
blood. The normalized expression of each of the miRNA pairs 
exhibits a body fluid-specific expression pattern which allows 
for an identification of the body fluid of interest. 
The respective miRNA assays successfully detected the 
presence of biological material in aged and environmentally 
compromised samples as well as in simulated casework 
samples that included admixed body fluid samples, post coital 
samples and trace body fluid samples. Additional miRNA 
candidates for use in the body fluid identification assays can 
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-continued 
<400> SEQUENCE, 5 
ugagguagga gguuguauag uu 22 
<210> SEQ ID NO 6 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 
ugagguagua gauuguauag uu 22 
<210> SEQ ID NO 7 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
ugagguagua guuuguacag uu 22 
<210> SEQ ID NO 8 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 8 
ugagguagua guuugugcug uu 22 
<210> SEQ ID NO 9 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 9 
uggaagacua gugauuuugu ugu 23 
<210> SEQ ID NO 10 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 10 
uagcagcaca uaaugguuug ug 22 
<210> SEQ ID NO 11 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 11 
uagcagcaca ucaugguuua ca 22 
<210> SEQ ID NO 12 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 12 
uagcagcacg uaaauauugg cg 22 
<210> SEQ ID NO 13 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
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-continued 
<400> SEQUENCE, 13 
caaagugcuu acagugcagg uag 23 
<210> SEQ ID NO 14 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 14 
uaaggugcau cuagugcaga uag 23 
<210> SEQ ID NO 15 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 15 
uaaggugcau cuagugcagu uag 23 
<210> SEQ ID NO 16 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 16 
acugcccuaa gugcuccuuc ugg 23 
<210> SEQ ID NO 17 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 17 
ugugcaaauc uaugcaaaac uga 23 
<210> SEQ ID NO 18 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 18 
uaaagugcuu auagugcagg uag 23 
<210> SEQ ID NO 19 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 19 
cauugcacuu gucucggucu ga 22 
<210> SEQ ID NO 20 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 20 
uucaaguaau ucaggauagg u 21 
<210> SEQ ID NO 21 
<211> LENGTH, 22 
<212> TYPE, RNA 
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-continued 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 21 
uguaaacauc cuacacucag cu 22 
<210> SEQ ID NO 22 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 22 
uguaaacauc cucgacugga ag 22 
<210> SEQ ID NO 23 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 23 
uguaaacauc cuugacugga ag 22 
<210> SEQ ID NO 24 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 24 
caaagugcug uucgugcagg uag 23 
<210> SEQ ID NO 25 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 25 
uuuggcacua gcacauuuuu gcu 23 
<210> SEQ ID NO 26 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 26 
agcagcauug uacagggcua uga 23 
<210> SEQ ID NO 27 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 27 
aaaagugcuu acagugcagg uag 23 
<210> SEQ ID NO 28 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 28 
uaaagugcug acagugcaga u 21 
<210> SEQ ID NO 29 
<211> LENGTH, 23 
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<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 29 
agcagcauug uacagggcua uca 23 
<210> SEQ ID NO 30 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 30 
ucguaccgug aguaauaaug cg 22 
<210> SEQ ID NO 31 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 31 
cauuauuacu uuugguacgc g 21 
<210> SEQ ID NO 32 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 32 
ucacagugaa ccggucucuu u 21 
<210> SEQ ID NO 33 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 33 
cagugcaaug uuaaaagggc au 22 
<210> SEQ ID NO 34 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 34 
ucagugcacu acagaacuuu gu 22 
<210> SEQ ID NO 35 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 35 
ucagugcauc acagaacuuu gu 22 
<210> SEQ ID NO 36 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 36 
aaaguucuga gacacuccga cu 22 
<210> SEQ ID NO 37 
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-continued 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 37 
aaguucuguu auacacucag gc 22 
<210> SEQ ID NO 38 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 38 
ucucccaacc cuuguaccag ug 22 
<210> SEQ ID NO 39 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 39 
ucgaggagcu cacagucuag u 21 
<210> SEQ ID NO 40 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 40 
cuagacugaa gcuccuugag g 21 
<210> SEQ ID NO 41 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 41 
aacauucaac gcugucggug agu 23 
<210> SEQ ID NO 42 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 42 
aacauucaac cugucgguga gu 22 
<210> SEQ ID NO 43 
<211> LENGTH, 24 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 43 
uuuggcaaug guagaacuca cacu 24 
<210> SEQ ID NO 44 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 44 
ugguucuaga cuugccaacu a 21 
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<210> SEQ ID NO 45 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 45 
uauggcacug guagaauuca cu 22 
<210> SEQ ID NO 46 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 46 
uggagagaaa ggcaguuccu ga 22 
<210> SEQ ID NO 47 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 47 
ugauauguuu gauauauuag gu 22 
<210> SEQ ID NO 48 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 48 
caacggaauc ccaaaagcag cug 23 
<210> SEQ ID NO 49 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 49 
uguaacagca acuccaugug ga 22 
<210> SEQ ID NO 50 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 50 
uagcagcaca gaaauauugg c 21 
<210> SEQ ID NO 51 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 51 
cugugcgugu gacagcggcu ga 22 
<210> SEQ ID NO 52 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 52 
augaccuaug aauugacaga c 21 
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<210> SEQ ID NO 53 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 53 
cagugcaaua guauugucaa age 23 
<210> SEQ ID NO 54 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 54 
cagugcaaug auauugucaa age 23 
<210> SEQ ID NO 55 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 55 
acugccccag gugcugcugg 20 
<210> SEQ ID NO 56 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 56 
gccccugggc cuauccuaga a 21 
<210> SEQ ID NO 57 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 57 
cuagguaugg ucccagggau cc 22 
<210> SEQ ID NO 58 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 58 
ucccuguccu ccaggagcuc acg 23 
<210> SEQ ID NO 59 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 59 
ugagcgccuc gacgacagag ccg 23 
<210> SEQ ID NO 60 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 60 
uuauaaagca augagacuga uu 22 
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<210> SEQ ID NO 61 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 61 
cggguggauc acgaugcaau uu 22 
<210> SEQ ID NO 62 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 62 
uuauaauaca accugauaag ug 22 
<210> SEQ ID NO 63 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 63 
aaugacacga ucacucccgu uga 23 
<210> SEQ ID NO 64 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 64 
uccuguacug agcugccccg ag 22 
<210> SEQ ID NO 65 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 65 
cggggcagcu caguacagga u 21 
<210> SEQ ID NO 66 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 66 
uaauccuugc uaccugggug aga 23 
<210> SEQ ID NO 67 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 67 
ucagcaaaca uuuauugugu gc 22 
<210> SEQ ID NO 68 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 68 
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aaaaguaauu gugguuuuug cc 22 
<210> SEQ ID NO 69 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 69 
caaaaaccac aguuucuuuu gc 22 
<210> SEQ ID NO 70 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 70 
auauuaccau uagcucaucu uu 22 
<210> SEQ ID NO 71 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 71 
gaugagcuca uuguaauaug ag 22 
<210> SEQ ID NO 72 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 72 
aagaugugga aaaauuggaa UC 22 
<210> SEQ ID NO 73 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 73 
auucuaauuu cuccacgucu uu 22 
<210> SEQ ID NO 74 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 74 
uucauuuggu auaaaccgcg auu 23 
<210> SEQ ID NO 75 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 75 
uugagaauga ugaaucauua gg 22 
<210> SEQ ID NO 76 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 76 
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ucuuguguuc ucuagaucag u 21 
<210> SEQ ID NO 77 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 77 
gagcuuauuc auaaaagugc ag 22 
<210> SEQ ID NO 78 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 78 
uaauuuuaug uauaagcuag u 21 
<210> SEQ ID NO 79 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 79 
cacaagguau ugguauuacc u 21 
<210> SEQ ID NO 80 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 80 
gugagucucu aagaaaagag ga 22 
<210> SEQ ID NO 81 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 81 
uuuaggauaa gcuugacuuu ug 22 
<210> SEQ ID NO 82 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 82 
aauggcgcca cuaggguugu g 21 
<210> SEQ ID NO 83 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 83 
uacccauugc auaucggagu ug 22 
<210> SEQ ID NO 84 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 84 
aaucauacac gguugaccua uu 
<210> SEQ ID NO 85 
<211> LENGTH, 21 
<212> TYPE, RNA 
51 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 85 
guucaaaucc agaucuauaa c 
<210> SEQ ID NO 86 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 86 
aucacauugc cagggauuuc c 
<210> SEQ ID NO 87 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 87 
aucacauugc cagggauuac c 
<210> SEQ ID NO 88 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 88 
uucacagugg cuaaguucug c 
<210> SEQ ID NO 89 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 89 
aggcaagaug cuggcauagc u 
<210> SEQ ID NO 90 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 90 
gugcauugua guugcauugc a 
<210> SEQ ID NO 91 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 91 
gugcauugcu guugcauugc 
<210> SEQ ID NO 92 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 











<400> SEQUENCE, 92 
uucaacgggu auuuauugag ca 
<210> SEQ ID NO 93 
<211> LENGTH, 22 
<212> TYPE, RNA 
53 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 93 
acaggugagg uucuugggag cc 
<210> SEQ ID NO 94 
<211> LENGTH, 24 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 94 
ucccugagac ccuuuaaccu guga 
<210> SEQ ID NO 95 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 95 
ucccugagac ccuaacuugu ga 
<210> SEQ ID NO 96 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 96 
acuccauuug uuuugaugau gga 
<210> SEQ ID NO 97 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 97 
uaacacuguc ugguaaagau gg 
<210> SEQ ID NO 98 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 98 
ugagaugaag cacuguagcu c 
<210> SEQ ID NO 99 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 99 
uagguuaucc guguugccuu cg 
<210> SEQ ID NO 100 
<211> LENGTH, 23 
<212> TYPE, RNA 
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<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 100 
aacauucauu gcugucggug ggu 23 
<210> SEQ ID NO 101 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 101 
ugccuacuga gcugauauca gu 22 
<210> SEQ ID NO 102 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 102 
aacuggcccu caaagucccg cu 22 
<210> SEQ ID NO 103 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 103 
acaguagucu gcacauuggu ua 22 
<210> SEQ ID NO 104 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 104 
cccaguguuc agacuaccug uuc 23 
<210> SEQ ID NO 105 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 105 
cccaguguuu agacuaucug uuc 23 
<210> SEQ ID NO 106 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 106 
uaauacugcc ugguaaugau ga 22 
<210> SEQ ID NO 107 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 107 
uaauacugcc ggguaaugau gga 23 
<210> SEQ ID NO 108 
<211> LENGTH, 22 
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<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 108 
gugaaauguu uaggaccacu ag 22 
<210> SEQ ID NO 109 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 109 
uugugcuuga ucuaaccaug u 21 
<210> SEQ ID NO 110 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 110 
ugucaguuug ucaaauaccc ca 22 
<210> SEQ ID NO 111 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 111 
cuccuauaug augccuuucu UC 22 
<210> SEQ ID NO 112 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 112 
gaacggcuuc auacaggagu u 21 
<210> SEQ ID NO 113 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 113 
aucacacaaa ggcaacuuuu gu 22 
<210> SEQ ID NO 114 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 114 
gaaguuguuc gugguggauu cg 22 
<210> SEQ ID NO 115 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 115 
acuucaccug guccacuagc cgu 23 
<210> SEQ ID NO 116 
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<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 116 
agcucggucu gaggccccuc agu 23 
<210> SEQ ID NO 117 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 117 
ugaggggcag agagcgagac uuu 23 
<210> SEQ ID NO 118 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 118 
uagugcaaua uugcuuauag ggu 23 
<210> SEQ ID NO 119 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 119 
aaaccguuac cauuacugag uu 22 
<210> SEQ ID NO 120 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 120 
ucaggcucag uccccucccg au 22 
<210> SEQ ID NO 121 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 121 
auuccuagaa auuguucaua 20 
<210> SEQ ID NO 122 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 122 
uaauacuguc ugguaaaacc gu 22 
<210> SEQ ID NO 123 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 123 
ugucuugcag gccgucaugc a 21 
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<210> SEQ ID NO 124 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 124 
aacuguuugc agaggaaacu ga 22 
<210> SEQ ID NO 125 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 125 
cucaucugca aagaaguaag ug 22 
<210> SEQ ID NO 126 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 126 
ugaaacauac acgggaaacc UC 22 
<210> SEQ ID NO 127 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 127 
cagcagcaca cugugguuug u 21 
<210> SEQ ID NO 128 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 128 
ccucuagaug gaagcacugu cu 22 
<210> SEQ ID NO 129 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 129 
cuaauaguau cuaccacaau aaa 23 
<210> SEQ ID NO 130 
<211> LENGTH, 24 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 130 
acugggggcu uucgggcucu gcgu 24 
<210> SEQ ID NO 131 
<211> LENGTH, 24 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 131 
aaagacauag gauagaguca ccuc 24 
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<210> SEQ ID NO 132 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 132 
aagugugcag ggcacuggu 19 
<210> SEQ ID NO 133 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 133 
uucccuuugu cauccuucgc cu 22 
<210> SEQ ID NO 134 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 134 
agaucgaccg uguuauauuc gc 22 
<210> SEQ ID NO 135 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 135 
aucauagagg aaaauccacg u 21 
<210> SEQ ID NO 136 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 136 
aucauagagg aaaauccaug uu 22 
<210> SEQ ID NO 137 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 137 
ugguagacua uggaacguag g 21 
<210> SEQ ID NO 138 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 138 
gugacaucac auauacggca gc 22 
<210> SEQ ID NO 139 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 139 
uuuugcaccu uuuggaguga a 21 
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<210> SEQ ID NO 140 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 140 
uacccuguag aaccgaauuu gug 23 
<210> SEQ ID NO 141 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 141 
aacccguaga uccgaucuug ug 22 
<210> SEQ ID NO 142 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 142 
aacccguaga uccgaacuug ug 22 
<210> SEQ ID NO 143 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 143 
uauggcuuuu uauuccuaug uga 23 
<210> SEQ ID NO 144 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 144 
uauggcuuuu cauuccuaug uga 23 
<210> SEQ ID NO 145 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 145 
ucuggcuccg ugucuucacu CCC 23 
<210> SEQ ID NO 146 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 146 
uucccuuugu cauccuaugc cu 22 
<210> SEQ ID NO 147 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 147 
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uggcagugua uuguuagcug gu 22 
<210> SEQ ID NO 148 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 148 
aggcagugua uuguuagcug gc 22 
<210> SEQ ID NO 149 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 149 
ugauuguagc cuuuuggagu aga 23 
<210> SEQ ID NO 150 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 150 
uacuccagag ggcgucacuc aug 23 
<210> SEQ ID NO 151 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 151 
uucacaggga ggugucau 18 
<210> SEQ ID NO 152 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 152 
aucgugcauc ccuuuagagu gu 22 
<210> SEQ ID NO 153 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 153 
cucuagaggg aagcacuuuc UC 22 
<210> SEQ ID NO 154 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 154 
caaagugccu cccuuuagag ug 22 
<210> SEQ ID NO 155 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 155 
aagugccucc uuuuagagug uu 
<210> SEQ ID NO 156 
<211> LENGTH, 22 
<212> TYPE, RNA 
69 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 156 
aaagugcuuc ccuuuggacu gu 
<210> SEQ ID NO 157 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 157 
aaagugcuuc cuuuuugagg g 
<210> SEQ ID NO 158 
<211> LENGTH, 24 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 158 
acaaagugcu ucccuuuaga gugu 
<210> SEQ ID NO 159 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 159 
acaaagugcu ucccuuuaga gu 
<210> SEQ ID NO 160 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 160 
uacugcagac guggcaauca ug 
<210> SEQ ID NO 161 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 161 
ugauugguac gucugugggu ag 
<210> SEQ ID NO 162 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 162 
auugacacuu cugugaguag a 
<210> SEQ ID NO 163 
<211> LENGTH, 18 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
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<400> SEQUENCE, 163 
ugcuuccuuu cagagggu 18 
<210> SEQ ID NO 164 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 164 
cugcaaaggg aagcccuuuc 20 
<210> SEQ ID NO 165 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 165 
gaaagcgcuu cccuuugcug ga 22 
<210> SEQ ID NO 166 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 166 
caaagcgcuu cucuuuagag ugu 23 
<210> SEQ ID NO 167 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 167 
aaagcgcuuc ccuucagagu g 21 
<210> SEQ ID NO 168 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 168 
uucuccaaaa gggagcacuu UC 22 
<210> SEQ ID NO 169 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 169 
cuacaaaggg aagcccuuuc 20 
<210> SEQ ID NO 170 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 170 
aaagugcuuc ucuuuggugg gu 22 
<210> SEQ ID NO 171 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 171 
gaaggcgcuu cccuuuggag u 
<210> SEQ ID NO 172 
<211> LENGTH, 22 
<212> TYPE, RNA 
73 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 172 
cuacaaaggg aagcacuuuc uc 
<210> SEQ ID NO 173 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 173 
cucuagaggg aagcacuuuc ug 
<210> SEQ ID NO 174 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 174 
ugacaacuau ggaugagcuc u 
<210> SEQ ID NO 175 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 175 
cuucuugugc ucuaggauug u 
<210> SEQ ID NO 176 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 176 
gcgaggaccc cucggggucu gac 
<210> SEQ ID NO 177 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 177 
uggcaguguc uuagcugguu gu 
<210> SEQ ID NO 178 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 178 
uaaggcacgc ggugaaugcc 
<210> SEQ ID NO 179 
<211> LENGTH, 23 
<212> TYPE, RNA 
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<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 179 
aaagugcugc gacauuugag cgu 23 
<210> SEQ ID NO 180 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 180 
aaugcaccug ggcaaggauu ca 22 
<210> SEQ ID NO 181 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 181 
auccuugcua ucugggugcu a 21 
<210> SEQ ID NO 182 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 182 
aacgcacuuc ccuuuagagu gu 22 
<210> SEQ ID NO 183 
<211> LENGTH, 20 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 183 
auguauaaau guauacacac 20 
<210> SEQ ID NO 184 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 184 
gagccaguug gacaggagc 19 
<210> SEQ ID NO 185 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 185 
uacccuguag auccgaauuu gug 23 
<210> SEQ ID NO 186 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 186 
uuauugcuua agaauacgcg uag 23 
<210> SEQ ID NO 187 
<211> LENGTH, 22 
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<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 187 
uccuucauuc caccggaguc ug 22 
<210> SEQ ID NO 188 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 188 
uggaauguaa ggaagugugu gg 22 
<210> SEQ ID NO 189 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 189 
auaagacgag caaaaagcuu gu 22 
<210> SEQ ID NO 190 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 190 
auaagacgaa caaaagguuu gu 22 
<210> SEQ ID NO 191 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 191 
aaaucucugc aggcaaaugu ga 22 
<210> SEQ ID NO 192 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 192 
uaaucucagc uggcaacugu ga 22 
<210> SEQ ID NO 193 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 193 
uaagugcuuc cauguuuugg uga 23 
<210> SEQ ID NO 194 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 194 
acuuuaacau ggaagugcuu UC 22 
<210> SEQ ID NO 195 
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<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 195 
uaagugcuuc cauguuucag ugg 23 
<210> SEQ ID NO 196 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 196 
uuuaacaugg ggguaccugc ug 22 
<210> SEQ ID NO 197 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 197 
ugucugcccg caugccugcc ucu 23 
<210> SEQ ID NO 198 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 198 
agaucagaag gugauugugg cu 22 
<210> SEQ ID NO 199 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 199 
uuucaagcca gggggcguuu uuc 23 
<210> SEQ ID NO 200 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 200 
uuaagacuug cagugauguu u 21 
<210> SEQ ID NO 201 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 201 
aacaucacag caagucugug cu 22 
<210> SEQ ID NO 202 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 202 
ugauugguac gucugugggu ag 22 
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<210> SEQ ID NO 203 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 203 
uacucaggag aguggcaauc ac 22 
<210> SEQ ID NO 204 
<211> LENGTH, 24 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 204 
uucuccaaaa gaaagcacuu ucug 24 
<210> SEQ ID NO 205 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 205 
ucucuggagg gaagcacuuu cug 23 
<210> SEQ ID NO 206 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 206 
aaagugcauc cuuuuagagg uu 22 
<210> SEQ ID NO 207 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 207 
cucuagaggg aagcgcuuuc ug 22 
<210> SEQ ID NO 208 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 208 
cuccagaggg augcacuuuc u 21 
<210> SEQ ID NO 209 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 209 
gaaggcgcuu cccuuuagag cg 22 
<210> SEQ ID NO 210 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 210 
cucuugaggg aagcacuuuc ugu 23 
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<210> SEQ ID NO 211 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 211 
caagaaccuc aguugcuuuu gu 22 
<210> SEQ ID NO 212 
<211> LENGTH, 22 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 212 
aaaaguaauu gugguuuugg cc 22 
<210> SEQ ID NO 213 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 213 
gcgacccacu cuugguuucc a 21 
<210> SEQ ID NO 214 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 214 
aaaacgguga gauuuuguuu u 21 
<210> SEQ ID NO 215 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 215 
uagauaaaau auugguaccu g 21 
<210> SEQ ID NO 216 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 216 
acuuacagac aagagccuug CUC 23 
<210> SEQ ID NO 217 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 217 
aggcugcgga auucaggac 19 
<210> SEQ ID NO 218 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 218 
aaacuacuga aaaucaaaga u 21 
<210> SEQ ID NO 219 
<211> LENGTH, 22 
<212> TYPE, RNA 
85 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 219 
acuuguaugc uagcucaggu ag 
<210> SEQ ID NO 220 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 220 
guggcugcac ucacuuccuu c 
<210> SEQ ID NO 221 
<211> LENGTH, 25 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 221 
ggcggaggga aguagguccg uuggu 
<210> SEQ ID NO 222 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 222 
caguaacaaa gauucauccu ugu 
<210> SEQ ID NO 223 
<211> LENGTH, 23 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 223 
uucucgagga aagaagcacu uuc 
<210> SEQ ID NO 224 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 224 
aggguaagcu gaaccucuga u 
<210> SEQ ID NO 225 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 225 
ugagcugcug uaccaaaau 
<210> SEQ ID NO 226 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 226 
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aguuaaugaa uccuggaaag u 
<210> SEQ ID NO 227 
<211> LENGTH, 21 
<212> TYPE, RNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 227 
uuuccauagg ugaugaguca c 
The invention claimed is: 
1. A method for determining the type of a forensic sample, 15 
comprising: 
a. obtaining RNA from the forensic sample; and 
b. analyzing expression of at least two marker miRNAs or 
isoforms thereof, in the forensic sample, ' 
wherein based on the expression of the miRNAs, or iso- 20 
forms thereof, the type of forensic sample is determined 
to be blood, menstrual blood, semen, vaginal secretion 
or saliva 
and wherein determining the sample is blood comprises 
analyzing expression of at least two miRNAs listed in 25 
Table 1, determining the sample is menstrual blood com-
prises analyzing expression of at least two miRNAs 
listed in Table 2, determining the sample is semen com-
prises analyzing expression of at least two miRNAs 
listed in Table 3, determining the sample is vaginal 30 
secretion comprises analyzing expression of at least two 
miRNAs listed in Table 4, and determining the sample is 
saliva comprises analyzing expression of at least two 
miRNAs listed in Table 5. 
2. The method according to claim 1, comprising analyzing 35 
at least three marker miRNAs. 
3. The method according to claim 1, wherein 
a. the miRNAs, or isoforms thereof, are expressed in the 
forensic sample and serve as a marker; 
b. the miRNAs, or isoforms thereof, show a discriminating/ 40 
differential expression pattern in a particular type of 
forensic sample compared to other types of forensic 
samples; 
c. the miRNAs, or isoforms thereof, are specifically 
expressed in a particular type of forensic sample; and/or 45 
d. the miRNAs, or isoforms thereof, are expressed in higher 
abundance in a particular type of forensic sample. 
4. The method according to claim 1, wherein at least two 
marker miRNAs, or isoforms thereof, are detected as markers 
for one particular forensic sample type, and/or wherein at 
21 
21 
least ~o marker miRNAs, or isoforms thereof, specific for 
each d1ff~rent.forensic sample type are analyzed in parallel in 
order to identify the type of forensic sample. 
5. The method according to claim 1, wherein 
a. the at least two miRNAs, or isoforms thereof, for deter-
mining blood are selected from the group consisting of 
miR15a, Let7i, miR15b, miR16, miR106a, miR106b, 
miR126, miR182, miR182*, miR185 miR190 
miR195, miR374, miR451, miR545 miR624 miR627' 
miR154*, andmiR607; ' ' ' 
b. the at least two miRNAs, or isoforms thereof, for deter-
mining menstrual blood are selected from the group 
consisting of miR33, miR23a/b miR95 miR106b 
miR154, miR218, miR377, miR4i'2, miR423, miR425~ 
3p, miR451, miR452, miR452* miR484 miR494 
miR648, miR369-5p, miR507, and miR648;' ' 
c. the at least two miRNAs, or isoforms thereof, for deter-
mining semen are selected from the group consisting of 
miRlOb, miR99a, miR135a, miR135b, miR204, 
miR508, miR513, miR517a, miR518f*, miR519d, 
miR520a*, miR520g/h, miR514, miR518c miR518e 
miR524*, andmiR611; ' ' 
d. the at least two miRNAs, or isoforms thereof, for deter-
mining vaginal secretion are selected from the group 
consisting ofmiR195, miR124a, miR372, miR521, and 
miR568; and/or 
e. the at least two miRNAs, or isoforms thereof for deter-
mining saliva are selected from the group co~sisting of 
miR205, miR206, miR208, miR302c, miR509, 
miR510, miR515-5p, miR518c*, miR525, miR526b, 
miR551a, miR600, miR606, miR555, miR587, and 
miR658. 
6. The method of claim 1, further comprising reverse tran-
scribing the obtained RNA prior to the analyzing. 
7. The method of claim 6, further comprising quantifying 
the obtained RNA. 
* * * * * 
